Download - CURRICULUM VITAE HOWARD CRAIG HERRMANN, M.D. …CURRICULUM VITAE HOWARD CRAIG HERRMANN, M.D. HOME ADDRESS: 732 Great Springs Road Bryn Mawr, PA 19010 (610) 519-1353 OFFICE ADDRESS:

CURRICULUM VITAE

HOWARD CRAIG HERRMANN, M.D.

HOME ADDRESS: 732 Great Springs Road

Bryn Mawr, PA 19010

(610) 519-1353

OFFICE ADDRESS: PCAM South Pavilion 11-107

3400 Civic Center Boulevard

Philadelphia, PA 19104

Phone: (215) 662-2180

Fax: (215) 349-5894

E-mail: [email protected]

EDUCATION: 1973-77 A.B. Harvard College

(Biochemistry, summa cum laude)

1977-81 M.D. Harvard Medical School

(Physiology, cum laude)

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

1981-82 Intern in Medicine, Mass. General Hospital, Boston, MA

1982-84 Resident in Medicine, Mass. General Hospital, Boston, MA

1984-87 Fellowship in Cardiology, Mass. General Hospital, Boston, MA

FACULTY APPOINTMENTS:

1981-87 Clinical Fellow in Medicine, Harvard University, Boston, MA

1984-87 Clinical and Research Fellow in Cardiology, Harvard University

1987-93 Assistant Professor of Medicine,

University of Pennsylvania School of Medicine, Philadelphia, PA

Howard C. Herrmann M.D. 2

1993-99 Associate Professor of Medicine,


2000-15 Professor of Medicine


2011- Professor of Medicine in Surgery

Perelman School of Medicine of the University of Pennsylvania

2015- John W. Bryfogle Jr. Professor of Cardiovascular Medicine

Perelman School of Medicine of the University of Pennsylvania

HOSPITAL AND ADMINISTRATIVE APPOINTMENTS:

1987-92 Staff, Cardiac Catheterization Laboratory,

University of Pennsylvania Medical Center

1992-03 Director of Interventional Cardiology

University of Pennsylvania Medical Center

2005- Consultant, Children’s Hospital of Philadelphia

2010-13 Director Interventional Cardiology Training Program

2003- Director, Interventional Cardiology Program and

Cardiac Catheterization Laboratories

Hospital of the University of Pennsylvania

2007- Director, Transcatheter Aortic Valve Replacement Program

2015- Health System Director for Interventional Cardiology

SPECIALTY CERTIFICATION:

1985 Internal Medicine (ABIM)

1987 Cardiovascular Disease (ABIM)

2000, 2010 Interventional Cardiology (ABIM)

LICENSURE:

Pennsylvania MD-038173-E

AWARDS, HONORS, AND MEMBERSHIP IN HONORARY SOCIETIES:

1973 Bausch and Lomb Science Award

1974 Edwards Whitaker Prize, John Harvard Scholar

1975 Detur Prize


1976 Phi Beta Kappa (Junior Twelve)

1976 Dreyfus Foundation Fellowship

1977 A.B., Summa Cum Laude

1981 M.D., Cum Laude

1987 American College of Cardiology Research Travel Award

1988 Fellow of the American College of Cardiology

1989 Fellow, Council on Clinical Cardiology (Am. Heart Assoc.)

1992 Fellow, Society for Cardiac Angiography and Interv

1996 Best Doctors in America: Northeast Region

1997 Merck Faculty Distinguished Teaching Award

(University of Pa Cardiovascular Division)

1998 Louis Duhring Outstanding Clinical Specialist Award

(University of Pennsylvania School of Medicine)

1996-2002, 2007-16 Philadelphia Magazine's "Top Docs" list

2003-04 ACC Governor for Pennsylvania

2003-2015 Castle Connolly Guide to “America’s Top Doctors”

1999-2015 Best Doctors in America (selected to national listing)

2013 Philadelphia Super Doctors List

2015 Awarded Master Fellow of SCAI (MSCAI) designation

MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES:

National Societies:

American College of Cardiology

Member, Physician Workforce Committee (1994-98 )

Member, ACC/AHA Committe to revise CABG

guidelines (1997- )

Member, Ad Hoc Faculty Awards Committee

Member, Cardiac Catheterization Committee (1998- )

Governor for PA (2000-2003)

i2 Program Executive Committee (2011- )

Paul Dudley White Society

Society for Cardiac Angiography and Interventions

Andreas Gruntzig Society

Transcatheter Therapeutics

Scientific Committee 2004-

American Heart Association

Member, Clinical Cardiology Council

Program Committee, Interventional Cardiology for

Scientific Sessions 2004-2006

Local Societies:

Pa. ACC State Chapter

Member, Finance Committee (1992- )

Chair, 1997 Abstract Review Committee


Vice-President (2000-2001)

President (2002-2003)

National Scientific Committees:

Member, Endpoint Committee, Prism Study, Merck and Co., Inc.

Member, Endpoint Committee, Prism-Plus Study, Merck and

Co., Inc.

Member, Endpoint Committe, Crown stent study, Cordis Inc.

Member, Review and Adjudication Committee Cardiac Events,

Fosamax Fracture Intervention Trial, Merck and Co., Inc.

Chairman, Data Safety and Monitoring Board, A Multicenter

Study to Evaulate the Safety and Tolerability of

Tirofiban in Patients Undergoing Intracoronary Stent

Placement, Merck and Co., Inc.

Member, AHA/ACC Committee to revise the CABG Guidelines

Consultant:

Advisory Board (Clopidogrel), Bristol-Meyers Squibb

Acute Coronary Syndromes, Merck Research Labs

Acute Myocardial Infarction, Co-Med/Lilly

Scientific Advisory Board, National Acute Coronary Syndromes

Registry, Centocor / Eli Lilly

Executive Committee, TARGET Trial, Merck and Co., Inc.

Executive Committee, FINESSE Trial, Centocor, Inc.

National Expert Advisory Board on Erectile Dysfunction, Pfizer

Steering Committee, ADVANCE-MI, Cor/Millenium

Steering Committee, FREEDOM stent trial (Cordis/NIH)

Director, DSMB, EDGE 1, 2 and MEDAL studies (Merck)

Steering Committee, CLOSURE I trial (NMT, Inc.)

National Cardiovascular Advisory Board, Lilly-ICOS

Chairman, Scientific Review Committee, I-REVIVE and

BRAVEHEART percutaneous aortic valve studies (PVT, Inc.)

Executive Committee, TENACITY Trial (Guilford Pharm, Inc.)

Steering Committee, EARLY-ACS Trial (Millenium Pharm, Inc.)

Steering Committee, PROTECT-Genomics Substudy (2004)

American Heart Association:

Program Comm., Council on Clinical Cardiology (2004-06)

Program Comm., Bench to Bedside, 2004 Scientific Sessions

Team leader, Interventional Cardiology, 2004 Scientific Sess.

Chairman, Scientific Advisory Board, Endovalve, Inc. (2007- )

Steering Committee, CHAMPION Trial (The Medicines Co.) 2007-

Executive Committee, Structural Heart Disease Council, SCAI 2008-

ACC-i2 Program Executive Committee, 2011-

Co-Director, SCAI Fellows Course, 2012-2013

Director, SCAI Fellows Course 2014-

Chair, AHA Mission Lifeline, Philadelphia area 2013-

Partner 2 – Sapien 3 Steering Committee, member 2013-


ACC Annual Scientific Program Committee (Team Lead,

Structural/Mitral), 2015-2016.

Partner 3 Sapien 3 Steering Committee, 2016-

EDITORIAL POSITIONS:

1987- Reviewer, American Journal of Cardiology, Circulation,

Catheterization and Cardiovascular Diagnosis, Journal

American College of Cardiology, Annals of Internal Medicine,

New England Journal of Medicine, Journal of Sexual

Medicine, Journal of the Amercian Medical Association,

Lancet

1994- Deputy Editor, NEJM Journal Watch for Cardiology (monthly

professional newsletter from the publishers of the

New England Journal of Medicine)

1995- Editorial Board, Catheterization and Cardiovascular Interventions

1997-2003 Editor, Heart Watch (monthly consumer newsletter from the

publishers of the New England Journal of Medicine)

2000- Editorial Board, Journal of Invasive Cardiology

2000- Editorial Board, theheart.org

2001- Editorial Board, Journal of Interventional Cardiology

2004-2006 Advisory Panel, North American Center for CME Cardiology

2005-2008 Editorial Board, Circulation

2011- Editorial Board, Circulation: Cardiovascular Interventions

2011- Editorial Advisory Board, Cardiac Today Intervention

2012- Section Editor, Transcatheter Aortic Valve Replacement

Journal of Invasive Cardiology

2014- Section Editor, Valvular Heart Disease,

Journal of the American College of Cardiology

ACADEMIC COMMITTEES AT THE UNIVERSITY OF PENNSYLVANIA:

1991-94 Internship Selection Committee

1993-96 Human Studies Committee-Institutional Review Board

1996- Critical Pathways Committees for CABG, PTCA

1997 Central Fee Abstraction QA Committee

1998 Pharmacy committee to evaluate LMW heparin

1998 Dept Medicine Quality Improvement Committee

1998-99 Chair-elect, Medical Faculty Senate Exec. Committee

1998- Leadership Committee, Faculty 2000

1998- Chairman, Catheterization Lab Supply Chain Project

1999-00 Chairman, Medical Faculty Senate Steering Committee

1999-00 Academic Review Committee


2000 Arthur Anderson committee to review the School of Medicine

Budget

2011- University Based Clinical Leadership Committee, Cardiology

2013- Department of Medicine CEQI Committee

2014 Committee to review clinical research at Penn Medicine

2015- Clinical Research Operations Committee

2016- New Patient Pavilion Planning Committee

MAJOR TEACHING AND CLINICAL RESPONSIBILITIES (CURRENT):

1. Course Director, weekly Combined Cardiovascular and Cardiac Surgical

Divisions Clinical conference.

2. Coronary Care Unit and Cardiology Consult Service, Attending Rounds,

2 months/year.

3. Cardiac Catheterization Laboratory Attending, 9 months/year.

4. Curriculum 2000 Cardiology Course, 2 lectures/year, workshop preceptor

5. Lecturer, Fellows Core Curriculum Course, Annual

6. Lecturer, House Staff Management Conference, Annual

7. Course Director, Penn Cardiac Valve Symposium, Phila, PA (Sept, 2004)


LECTURES BY INVITATION (PAST 5 YEARS):

Jan 25, 2007, “Optimizing Patient Outcomes in ACS and PCI,” Grand Rounds,

Harrisburg General Hospital, Harrisburg, PA

Feb 9, 2007, “The Amplatzer Family of Devices.” Invited faculty lecture, CRT

2007, Washington DC

Feb 9, 2007, “Rationale and Feasibility of Percutaneous Mitral Valve

Replacement,” Invited faculty lecture, CRT 2007, Washington DC

March 13, 2007, “Use of Drug-Eluting Stents in Multivessel Disease and Off-

Label Situations,” Drexel Univ CME symposium, Phila, PA.

April 2, 2007, “Update on Percutaneous Mitral Valve Repair,” invited faculty,

Surgical Symposium (Dr. Subramanian), New York, NY.

May 30, 2007, “PFO and stroke,” invited lecture, Philadelphia Adult Congenital

Heart Disease national symposium.

June 1, 2007, “Will Percutaneous Therapies Replace Surgery for Mitral

Regurgitation?” Grand Rounds, Rhode Island Hospital, Brown School

of Medicine, Providence, RI.

June 26, 2007, “Will Percutaneous Therapies Replace Surgery for Mitral

Regurgitation?” CME dinner symposium, Washington Hospital Center,

Washington DC.

June 27, 2007, “Optimizing Adjunctive Therapies for ACS and PCI,”

Cardiology Catheterization Conference, Washington Hospital Center,

Washington DC.

July 23, 2007, “Technique of Transseptal Catheterization,” Invited faculty

speaker at Pediatric-Adult Interventional Cardiology Symposium, Las

Vegas, NV

July 24, 2007, “Overview of Percutaneous Mitral Repair Technologies,” Invited

faculty speaker at Pediatric-Adult Interventional Cardiology

Symposium, Las Vegas, NV

Sept 14, 2007, “Will Percutaneous Therapies Replace Surgey for MR?”, and

“Evolving Strategies in Acute MI” at Pri-Med CME Symposium

Cardiac Update, White Plains, NY


Sept 20, 2007, “Percutaneous Valve Repair and Replacement,” Delaware Valley

Echo Society, Philadelphia, PA

Oct 9, 2007, “Percutaneous Mitral Valve Replacment and Other Options, NY

ACE Meeting, NYC, NY

Oct 17, 2007, “Is There a Role for Facilitated PCI in 2007,” PA ACC State

Chapter Door-to-Balloon Conference, Hershey, PA.

Oct 20-24, 2007, TCT (Transcatheter Therapeutics) Conference, Washington

DC, 13 assorted presentations.

Nov 11, 2007, Optimizing Outcomes in ACS and PCI, Grand Rounds, Sentara

Norfolk General Hospital, Norfolk, VA

February 11, 2008, “Percutaneous Mitral Valve Replacement,” CRT

Symposium, Washington DC

March 29, 2008, “Co-Chair, ACC Symposium on Percutaneous Valve Therapies,

ACC National Convention, Chicago, Il

March 31, 2008, “Understanding Surgical Results for MR,” ACC Symposium,

Chicago, Il.

April 5, 2008, “Percutaneous Valve Repair and Replacement,” University of PA

Cardiology Update Symposium, Absecon, NJ

April 14, 2008, “Percutaneous Valve Repair and Replacement,” Grand Rounds,

Children’s Hospital of Philadelphia, Philadelphia, PA

April 17, 2007, “Percutaneous Valve Repair and Replacement,” Grand Rounds,

Presbyterian Medical Center, Philadelphia, PA

May 6, 2008, “Tips and Tricks for Transcatheter Aortic Valve Replacement,” at

Valvular Heart Disease Mayo Clinic and Heart Valve Society of

America Symposium, Las Vegas, NV

May 7, 2008, “Percutaneous Valve Repair and Replacement,” Mark Rosenthal

Memorial Lecture, Abington Hospital, Abington, PA.

May 30, 2008, “Emerging Trends in AMI Management,” Grand Rounds,

Bayonne Hospital, Bayonne, NJ.

June 6-7, 2008, Faculty, Transcatheter Valve Therapy, National Conference,

Seattle, WA


June 10-11, 2008, Faculty, Capital Cardiovascular Conference, Baltimore, MD

(“Percutaneous Valve Therapy, Alcohol Septal Ablation, Live case

moderator”)

July 17, 2008, “Management of Aortic Stenosis in 2008: Is There Still a Role for

Surgery?” Grand Rounds, Wilmington VA Hospital, Wilmington, DE

Sept 6, 2008, “Management of Aortic Stenosis in 2008: Is There Still a Role for

Surgery?” Pri-Med CME Physician Update, Washington DC.

Sept 12, 2008, “Management of Aortic Stenosis in 2008: Is There Still a Role

for Surgery?” Pri-Med CME Physician Update, Detroit, MI

Sept 13, 2008, “Percutaneous Therapies for Mitral Regurgitation,” Winthrop

Hospital Symposium on Structural Heart Disease, Mineola, NY

Sept 24, 2008, “New Management Strategies for Acute Myocardial Infarction,”

Grand Rounds, Hackettstown General Hospital, Hackettstown, NJ

Sept 25, 2008, “Management of Aortic Stenosis in 2008: Is There Still a Role

for Surgery?” Grand Rounds, Monmouth Medical Center, Long

Branch, NJ

Oct 12-16, 2008, Multiple presentations as faculty at TCT 2008

Oct 21, 2008, “Update on DES,” dinner symposium, Harrisburg, PA

Oct 22, 2008, “Percutaneous Valve Repair and Replacement,” Grand Rounds,

Harrisburg General Hospital, Harrisburg, PA

Oct 30, 2008, “Drug-Eluting Stent Update,” dinner symposium, Phila, PA

Nov 1, 2008, “Percutaneous Valve Repair and Replacement,” Keynote speaker,

Pennsylvania ACC Chapter annual meeting, Hershey, PA

Nov 3, 2008, “Percutaneous Valve Repair and Replacement,” Cardiology Grand

Rounds, Beth Israel Hospital, New York, NY

Nov 18, 2008, “Percutaneous Valve Repair and Replacement,” Cardiology Grand

Rounds, Montefiore Hospital, Bronx, NY

Dec 2, 2008, “Interventions for Structural and Valvular Heart Disease,” Medical

Grand Rounds, Medical Center at Princeton, Princeton, NJ

Dec 4, 2008, “Interventions for Structural and Valvular Heart Disease,”

Cardiology Grand Rounds, Bryn Mawr Hospital, Bryn Mawr, PA


Jan 22, 2009, “Management of Aortic Stenosis 2009: Transcatheter Aortic Valve

Implantation,” Grand Rounds, Hospital of the University of

Pennsylvania, Philadelphia, PA

Feb 27, 2009, “Transcatheter Aortic Valve Implantation,” Invited faculty,

PanVascular Summit, Park City, Utah

March 5. 2009, “Percutaneous Mitral Valve Replacement,” at CRT 2009, Invited

Faculty, Washington DC

March 28, 2009, “The Cardiac Cath Lab of the Future – Percutaneous Valvular

Therapies,” American College of Cardiology National Meeting, Invited

Speaker, Orlando, FL

March 31, 2009, “Percutaneous Therapies for Mitral Valve Disease,” Fellows

Bootcamp, American College of Cardiology National Meeting, Invited

Speaker, Orlando, FL

April 16, 2009, “Overview of Percutaneous Approaches to Treating Mitral

Regurgitation,” Invited Faculty, Concepts in Contemporary

Cardiovascular Medicine, Houston, TX

April 23, 2009, “Partner Trial – How We Do It at Upenn,” Invited Faculty,

Dallas-Liepzig Valve Meeting, Dallas, TX

April 24, 2009, “Percutaneous Mitral Valve Replacement,” Invited Faculty,

Dallas-Liepzig Valve Meeting, Dallas, TX

May 6, 2009, “A Critical Appraisal of Percutaneous Approaches to Mitral

Regurgitation,” Invited Faculty, Society for Cardiac Angiography and

Interventions, National Meeting, Las Vegas, NV

May 29, 2009, “Management of AS in 2009,” Pri-Med CME Symposium,

Philadelphia, PA

June 16, 2009, “Evolving Strategies in Acute MI Management,” Dinner

symposium, Reading, PA

June 17, 2009, “Transcatheter Aortic Valve Replacement: Results,” and “Live

Case Moderator,” Invited Faculty, C3 Symposium, Baltimore, MD

June 25, 2009, “Rationale for Transcatheter Mitral Valve Replacement,” “Update

on Endovalve, Inc.,” and “Update on Viacor PTMA,” Invited lectures,

Transcatheter Valve Therapies Meeting, Seattle, WA

Sept 9-12, 2009, Director, AATS and ACC Joint symposium, “Heart Valve

Summit,” Chicago, IL (multiple faculty lectures)


Sept 21-26, 2009, Featured Faculty, Transcatheter Therapeutics (TCT), San

Francisco, CA

Oct 6, 2009, “Update on Adjunctive Therapy for PCI,” lecture for fellows,

Cherry Hill, NJ

Oct 14, 2009, “Update on Adjunctive Therapy for PCI,” grand rounds at Kansas

City, MO

Oct 15, 2009, “Percutaneous Heart Valve Repair and Replacement,” Cardiology

Grand Rounds, Mid-America Heart Institute, Kansas City, MO

Nov 5, 2009, ““Percutaneous Heart Valve Repair and Replacement,” Grand

Rounds, Hershey-Penn State Medical Center, Hershey, PA

Feb 21-22, 2010, Faculty, CRT Convention, Washington DC. (Multiple panels,

session moderations, talks)

Feb 25, 2010, “Transcatheter Mitral Valve Repair and Replacement,” Grand

Rounds, Hopital Laval, Quebec City, CA

March 14, 2010, Faculty, American Society of Echocardiography Symposium,

Atlanta, GA (Percutaneous Mitral Valve Therapies, Case Presentations

on Edge-to-Edge Mitral Repair and Transcatheter Aortic Valve

Implantation).

March 15-16, 2010, Invited speaker, Faculty, Moderator multiple sessions of the

American College of Cardiology and i2 National Convention, Atlanta,

GA

March 26, 2010, Invited speaker, Faculty, ICR Meeting, Baltimore, MD,

“Percutaneous Mitral Valve Repair and Replacement.”

April 15, 2010, Invited Faculty Speaker, Heart Valve Society Annual Meeting:

Valves in the Big Apple, “Percutaneous Therapy of Peri-Valvular

Leak,” New York, NY

April 23, 2010, Invited Faculty, Innovations Cardiac and Vascular Symposium,

“Therapeutic Alternatives for Aortic Stenosis and Mitral Regurgitation,

Guidelines for Treatment and New Advances,” Bethesda, MD

May 6,7, 2010, Invited Faculty, Society of Cardiac Angiography and Intervention

National Meeting, San Diego, CA (Moderator, C3 Fellows Symposium,

Lecturer on 3D TEE for Structural and Valvular Interventions,

Emerging Technology for Mitral Valve Therapies).


June 23, 2010, Invited Faculty, C3 Complex Cardiovascular Coronary

Symposium, “Transcatheter Aortic Valve Implantation,” Baltimore,

MD

Sept 21-25, 2010, Invited Faculty, Transcatheter Therapeutics, Washington DC,

“Imaging Guidance MitraClip,” “Opportunities for Transcatheter

Mitral Valve Repair,” “Low output Low gradient AS,” “Technical

Issues with Transcatheter AVI,” multiple panels and moderator

sessions.

Oct 6-9, 2010, Director, Heart Valve Summit, Sponsored by ACC/SCAI/AATS;

multiple sessions and lectures

Oct 21, 2010, Invited Faculty, Gore Helex Training Program, lecture on

“Imaging the Atrial Septum, Intracardiac Echo, Use of Closure Devices

for Atrial Septal Defects”

Nov 15, 2010, Invited lecture, American Heart Association Scientific Sessions,

Chicago, IL, “Transcatheter Mitral Valve Implantation.”

Dec 3, 2010, Invited Faculty, Society of Thoracic Surgery meeting on TAVI,

“Case Presentation,” and “Tips and Tricks for TAVI.”

Dec 9, 2010, Invited Faculty, Dallas-Leipzig Valve Meeting, Dallas, TX,

“Endovalve Transcatheter Mitral Valve Implantation,” “Low Output

Low Gradient Aortic Stenosis,” Moderator several sessions

Dec 15, 2010, Grand Rounds at Hahnemann Hospital, Philadelphia PA,

“Transcatheter Valve Therapy.”

Jan 5, 2011, Grand Rounds at California Pacific Medical Center, San Francisco,

CA, “Transcatheter Valve Therapy.”

Jan 5, 2011, Grand Rounds at UCSF Medical Center, San Francisco, CA,


Jan 18, 2011, Grand Rounds at Pennsylvania Hospital, Philadelphia, PA,


Feb 27-28, 2011, Invited Faculty, CRT Meeting, Washington DC.

March 9, 2011, Grand Rounds, University of Connecticut Medical Center,

Hartford, CT, “Transcatheter Valve Therapy.”

March 29, 2011, “Interventions for Structural Heart Disease,” Dinner symposium

for Kennedy Hospital Fellows and Staff, Cherry Hill, NJ


April 4, 2011, Invited Faculty, American College of Cardiology i2 Scientific

Sessions, New Orleans, LA.

May 4-6, 2011, Invited Faculty, Society for Cardiovascular Interventions and

Angiography, Baltimore, MD

May 25, 2011, “Transcatheter Therapy for Aortic Stenosis,” Grand Rounds,

Lankenau Hospital, Wynnewood, PA

June 3-4, 2011, Invited Faculty, STS Transcatheter Heart Valve Therapies

Meeting, Chicago, IL

June 6-8, 2011, Invited Faculty, Transcatheter Valve Therapeutics Meeting,

Vancouver, BC, Canada

June 10-12, 2011, Invited Faculty, American Society of Echocardiography

National Meeting, Montreal, Canada

Sept 8, 2011, “Interventions for Structural and Valvular Heart Disease,” Fellows

Course (sponsored by Gore Medical, Inc.), Newark, DE

Oct 13-15, 2011, Director, ACC/AATS/SCAI Heart Valve Summit, Chicago, IL

(multiple presentations on valvular heart disease)

Oct 21, 2011, Invited Faculty, Brigham and Women’s Valvular Heart Disease

Symposium, “Transcatheter Mitral Valve Repair and Replacement,”

Boston, MA

Nov 6-11, 2011, Invited Faculty, Transcatheter Therapeutics (TCT), multiple

presentations and chaired sessions, San Francisco, CA

Dec 9, 2011, Invited Faculty (presentations on pre-procedure planning and role of

TAVR), STS and ACC Transcatheter Valve Symposium, Washington

DC.

Jan 12, 2012, “Transcatheter Aortic Valve Replacement,” Grand Rounds,

Cardiovascular Division, Hospital of the University of Pennsylvania,

Philadelphia, PA.

Jan 21, 2012, “Transcatheter Valve Repair,” Invited Faculty, 12th Annual New

Frontiers in Heart Failure Therapy Symposium, New York Cardiology

Society, New York, NY.

Jan 27-29th, 2012, Invited Faculty, Mayo Clinic Structural Heart Disease

Symposium, Miami, Fl

Feb 5, 2012, Invited Faculty, CRT Meeting, Washington DC.


Feb 10, 2012, “Transcatheter Aortic Valve Replacement,” Grand Rounds,

Crozer-Chester Hospital, Chester, PA

Feb 11, 2012, “Minimally Invasive Valve Therapy,” Invited Faculty, Coastal

Cardiovascular Conference, Salisbury, MD.

Feb 13, 2012, “Transcatheter Valve Therapy,” Cardiology Grand Rounds,

Children’s Hospital of Philadelphia, Philadelphia, PA

Feb 25, 2012, Invited faculty, STS Transcatheter Aortic Valve Symposium,

Chicago, IL, lectures on “Tips and Tricks,” and “Radiation Safety”

March 3, 2012, “Transcatheter Aortic Valve Replacement 2012 – Ready for

Primetime?” Invited speaker, Christiana Medical Center Cardiovascular

Update Program

March 13, 2012, “Tips and Tricks in Transseptal Catheterization,” Fellows

Course (Boston Scientific Corp.).

March 25, 2012, Faculty, Live Cases ACC/i2 National Meeting

May 5, 2012, “Treatment of Aortic Stenosis in 2012,” Invited faculty,

Cardiovascular Update of Pa Hospital, Philadelphia, PA

June 2-5, 2012, Invited Faculty with multiple lectures, moderator and discussion

sessions, Transcatheter Valve Therapy national meeting, Seattle, WA

June 27-29, 2012, Invited faculty with multiple presentations to CSI in Frankfurt,

Germany

Sept 14, 2012, Webcast on new findings from the European Society of

Cardiology Meeting, Cardiovascular Research Foundation, New York,

NY

Sept 23, 2012, “Transcatheter Aortic Valve Replacement 2012,” Cardiology

Update CME program, CVI, Inc. Philadelphia, PA

Sept 28-29, 2012, ACC-STS TAVR Program, multiple lectures, Washington DC

Oct 11-13, 2012, ACC-STS-AATS Heart Valve Summit 2012, Director with

multiple lectures

Oct 22-26, 2012, Transcatheter Cardiovascular Therapeutics (TCT) 2012,

Multiple lectures, discussant, moderator sessions, Featured Faculty,

Miami, FL

Dec 5-7, 2012, Dallas-Leipzig Valve Course, Dallas TX, Invited faculty with

lectures on low flow aortic stenosis


Jan 20, 2013, Cardiovascular Institute Symposium on Imaging, invited faculty,

“Use of Imaging in Percutaneous Structural and Valvular

Interventions,” Philadelphia, PA

Jan 24-25, 2013, Mayo Clinic Symposium on Structural Heart Disease, Miami

Beach, FL. Invited faculty with multiple presentations.

Feb 23-25, 2013, Invited Faculty, CRT National Meeting, Washington DC

(multiple presentations)

March 10-12, 2013, Invited Faculty, ACC National Convention, San Francisco,

CA (i2TCT at ACC program committee), multiple presentations

March 19, 2013, Grand Rounds, Montefiore Hospital, New York City, “Current

and Future Trends in TAVR.”

May 9,10, 2013, Invited Faculty, SCAI National Meeting, Orlando Fl. Chair

TAVR mini-symposium, C3 Fellows Course

Sept 16, 2013, “Use of Medical Devices in Interventional Cardiology,” Wharton

School of Business course on medical device intervention, invited

lecture

Sept 26-28, 2013, Director and Faculty, ACC/AATS/SCAI Heart Valve

Symposium 2013, Chicago, IL (10 assigned presentations)

Oct 27-31, 2013, Faculty, TCT Meeting, San Francisco, CA. Multiple

presentations, moderations (13 assigned presentations).

Dec 7-9, 2013, SCAI Fall Fellows Course, Las Vegas, NV. Invited faculty with

multiple presentations

Jan 10, 2014, Director, Fellows Training Course in Transcatheter Heart Valve

Implantation, Philadelphia, PA

Jan 13-14, 2014. Yale University, Visiting Professor, Grand Rounds speaker,

“Current and Future Role of Interventions for Structural and Valvular

Heart Disease.”

Jan 16, 2014. Mayo Clinic CME course, Building the Heart Team, invited

faculty, “Functional MR, MitraClip, and the COAPT Trial,” Ft.

Lauderdale, FL

Feb 12, 2014, Pinnacle Health Harrisburg Hospital, Cardiac Grand Rounds,

“Current and Future Role of Interventions for Structural and Valvular

Heart Disease,” Harrisburg, PA


Feb 21-24, 2014. Invited faculty with multiple lectures to the CRT 2014

(Cardiovascular Research Technologies) national meeting, Washington

DC.

March 29-31, 2014, Invited lectures at national ACC convention, Washington

DC.

May 9, 2014, Director Fellows Training Course in Transcatheter Heart Valve

Implantation, Denver, CO

May 29-31, 2014, Invited lectures and Chair, C3 Summit, National Convention

of the Society for Cardiovascular Intervention and Angiography (SCAI)

July 25, 2014, Featured speaker at the national Siemens Innovations for Imaging

Convention, Orlando, FL

Sept 17-22, 2014, Faculty, TCT National Conference with 10 assignments,

Washington DC

Sept 23-35, 2014, Co-Director and Faculty, ACC and AATS Heart Valve

Summit, Chicago IL

Oct 26, 2014, “Update on Transcatheter Valve Therapy,” in the Interventional

Cardiovascular Medicine State of the Art 2014 Symposium,

Philadelphia, PA

Dec 1, 2014, Visiting Professor and Cardiology Grand Rounds, William

Beaumont Hospital, Royal Oak, MI, “Transcatheter Valve Therapy for

Mitral Regurgitation,” “Update on TAVR.”

Dec 6, 2014, Featured speaker at Westchester Medical Center’s Heart Valve

Symposium, “Percutaneous Mitral Valve Repair and Replacement”

Feb 18, 2015, Visiting Professor, Cardiology Division, Washington University in

St. Louis School of Medicine. Grand Rounds, “Transcatheter Therapy

of Mitral Regurgitation.

Feb 21-23, 2015, Invited Faculty, CRT 2015, Washington DC, multiple invited

lectures.

Feb 28, 2015, Faculty, Challenge the Chiefs Symposium, “Controversies in the

Interventional Management of STEMI Patients.”

March 5, 2015, Conner Invited Lecture in Structural Heart Disease: “Update and

Advances in TAVR,” Brown University, Providence, RI


March 6, 2015, Grand Rounds, Rhode Island Hospital of Brown University,

“Transcatheter Therapy of Mitral Regurgitation.”

March 14-16, 2015, Invited Faculty, Multiple presentations, American College

of Cardiology National Convention, San Diego, CA.

March 26, 2015, Invited lecture, Wharton Medical Devices Class on Innovation

in Interventional Cardiology, Philadelphia, PA

March 30, 2015, Cardiology Grand Rounds, Northwestern Medical Center,

Chicago, IL: “Transcatheter Therapy of MR”

April 16, 2015, Cardiology Grand Rounds, Hospital of the University of

Pennsylvania, Philadelphia, PA, “Transcatheter Therapy of MR.”

April 25, 2015, Invited lecture in Inova Hospital Cardiology Symposium,

“Updated on TAVR,” Washington DC.

May 7, 2015, Invited Faculty, Society for Cardiac Angiography and Interventions

national meeting, multiple presentations, San Diego, CA.

May 8, 2015, Chair, SCAI C3 Fellows Summit, San Diego, CA.

June 4-6, 2015, Invited Faculty, Transcatheter Valve Therapy Meeting, Chicago

IL, multiple presentations.

Oct 1-3, 2015, Director, AATS/ACC Heart Valve Summit, Chicago, IL, multiple

(6) presentations

Oct 11-15, 2015, Invited Faculty, Transcatheter Therapeutics National Meeting,

San Francisco, CA, multiple (14) presentations.

Oct 22, 2015, Dinner lecture on New Therapies for Structural and Valvular Heart

Disease, Philadelphia Angio Club, Philadelphia, PA

Oct 30, 2015, Faculty for Sapien 3 National Training Course, Philadelphia, PA

Nov 5, 2015, Faculty for Sapien 3 National Fellows Training Course, Miami, FL

Nov 9, 2015, Invited Faculty to National AHA Convention, “New Transcatheter

Therapies for Mitral Regurgitation, Orlando, FL

Nov 14, 2015, “Transcatheter Mitral Valve Therapy for MR,” Penn Cardiology at

PPMC Cardiology Update 2015, Galloway, NJ


Nov 21, 2015, “Transcatheter Therapy of MR and Update on TAVR,”

Westchester Medical Center Valve Disease Symposium, Rye Brook,

NY

Dec 3, 2015, “Transcatheter Therapy for Valvular Heart Disease,” Lourdes

Cardiology Fellows Dinner Symposium, Cherry Hill, NJ

Jan 27, 2016, “Transcatheter Therapy of MR,” Cardiology Grand Rounds,

Massachusetts General Hospital, Boston, MA

April 2-4, 2016, Invited Faculty, ACC National Convention, Chicago, IL,

April 11, 2016, “Transcatheter Therapy of MR – Hope or Hype,” Cardiology

Grand Rounds, Children’s Hospital of Philadelphia, Philadelphia, PA.

April 15, 2016, “Transcatheter Therapy of MR – Hope or Hype,” Invited speaker,

national Catholic Health Initiatives National Cardiology Conference,

Houston, TX

April 21, 2016, “Transcatheter Therapy of MR – Hope or Hype,” Cardiology

Grand Rounds, Presbyterian Medical Center of the University of

Pennsylvania, Philadelphia, PA

May 5-7, 2016, Invited Faculty, National Meeting of the Society of Cardiac

Intervention and Angiography, Orlando Fl (multiple talks)

June 16-17, 2016, Invited Faculty, Transcatheter Valve Therapeutics, Chicago, IL

(multiple invited lectures and panels).

July 21-Aug 8, 2016, Invited lectures, China:

Cardiac Imaging and Cardiac Intervention Summit, Beijing

July 23, 2016: “TAVR: Past, Present, and Future”

West China Hospital Cardiovascular Imaging Seminar, Chengdu

Aug 1, 2016: “Future of Structural Heart Disease Intervention”

Renji Hospital, Shanghai

Aug 4, 2016: “TAVR and Other Structural Heart Interventions”

October 1, 2016, “Is TAVR Ready for Low Risk Patients?” Invited faculty,

Westchester Medical Center Symposium on Valvular Heart Disease,

Westchester, NY.

October 4, 2016, “Update on Structural and Valvular Interventions at Penn,”

Princeton dinner symposium


October 15, 2016, “Transcatheter Mitral Valve Replacement – Where No Valve

Has Gone Before,” Invited Faculty, Scientific Symposium for the 100th

Anniversary of the Cardiac Unit, Mass General Hospital, Boston, MA

October 20-22, 2016, Director with multiple (7) presentations, ACC/AATS/STS

Heart Valve Summit, Chicago IL.

October 29-November 2 2016, Invited faculty with multiple (12) presentations at

national TCT convention, Washington DC.

Nov 10, 2016. Faculty Director, TAVR Fellows Course, New York, NY.

Nov 19, 2016, Honored Faculty Speaker, “Current Status Balloon-Expandable

TAVR,” National TAVR Users Meeting, Tokyo Japan.

Jan 14, 2017, Faculty at Baptist Health Structural Heart Symposium,

Jacksonville, FL: “Diagnosis and Management of Aortic Stenosis,” and

“Transcatheter Mitral Valve Therapy.”

February 15, 2017, Panelist at Leerink Global Healthcare Conference, NY

February 18-20, 2017, Invited Faculty with multiple presentations at CRT 2017,

Washington DC.

March 16, 2017, Invited Lecture, “Transcatheter Mitral Valve Replacement –

Hope or Hype,” Vascular Biology Working Group National

Symposium, Washington DC

March 17-19, 2017, Invited Faculty, American College of Cardiology national

scientific sessions, Washington DC


BIBLIOGRAPHY:

Research Publications, peer reviewed:

1. Parham P, Terhorst C, Herrmann HC, Humphreys RE, Waterfield MD, Strominger JL:

Immunological and chemical purity of papain solubilized HLA antigens. Proc Nat

Acad Sci USA 72:1594-98, 1975.

2. Strominger JL, Chess L, Herrmann HC, Humphreys RE, Malenka D, Mann D,

McCune JM, Parham P, Robb R, Springer TA, Terhorst C: Isolation of

histocompatibility antigens and of several B-cell specific proteins from cultured human

lymphocytes. Histocompatibility Testing, 1975, F. Kissmeyer-Nielson, (ed.),

Musksgaard, Copenhagen, pp. 719-30.

3. Humphreys RE, McCune JM, Chess L, Herrmann HC, Malenka D, Mann D, Parham

P, Schlossman S, Strominger JL: Isolation and immunologic characterization of a

human, B-lymphocyte specific cell surface antigen. J Exp Med 144:98-112, 1976.

4. Herrmann HC, Morris BJ, Reid IA: Effects of angiotensin II and sodium depletion on

angiotensinogen production. Am J Physiol 238 (Endo. Metab. 1): E145-E149, 1980.

5. Herrmann HC, Kelly J, Fried M, Strome M: The association of a hearing deficit with

Larsen's Syndrome. J Otolaryngology, 10(1):45-48, 1981.

6. Dzau VJ, Herrmann HC: Hormonal control of angiotensinogen production. Life

Sciences 30:577-584, 1982.

7. Herrmann HC, Dzau VJ: The feedback regulation of angiotensinogen production by

components of the renin-angiotensin system. Circ Res 52:328-334, 1983.

8. Herrmann HC, Kaplan LM, Bierer BE: Q-T prolongation and torsades de pointes

ventricular tachycardia produced by the tetracyclic anti-depressant Maprotiline. Am J

Cardiol, 51:904-906, 1983.

9. Herrmann HC, Ruddy TD, Dec GW, Strauss HW, Boucher CA, Fifer MA: Inotropic

effect of enoximone in patients with heart failure: Demonstration by left ventricular

end-systolic pressure-volume analysis. J Am Coll Cardiol 9:1117-23, 1987.

10. Herrmann HC, Ruddy TD, Dec GW, Boucher CA, Fifer MA: Diastolic function in

patients with severe heart failure: Comparison of the effects of enoximone and

nitroprusside. Circulation 75:1214-21, 1987.

11. Choong CY, Herrmann HC, Weyman AE, Fifer MA: Preload dependence of Doppler-

derived indexes of left ventricular diastolic function in humans. J Am Coll Cardiol

10:800-8, 1987.


12. Herrmann HC, Wilkins GT, Block PC, Palacios IF: Percutaneous balloon mitral

valvotomy for patients with mitral stenosis: analysis of factors influencing early

results. J Thoracic and Cardiovasc Surgery, 96:33-38, 1988.

13. Herrmann HC, Palacios IP, Dec GW, Scheer J, Fifer MA: Effects of atrial natriuretic

factor on coronary hemodynamics and myocardial energetics in man. American Heart

Journal, 115:1232-38, 1988.

14. Herrmann HC, Kussmaul WG, Hirshfeld JW. Single large-balloon percutaneous

balloon mitral valvuloplasty. Catheterization and Cardiovascular Diagnosis, 17:59-61,

1989.

15. Brady ST, Davis CA, Kussmaul WG, Laskey WK, Hirshfeld JW, Herrmann HC.

Morbidity and mortality of aortic valvuloplasty in patients 80 years of age and older.

Annals Int Med, 110:761-766, 1989.

16. Aroney CN, Herrmann HC, Semigran MJ, Dec GW, Fifer MA. Linearity of the end-

systolic pressure-volume relation in patients with severe heart failure. J Am Coll

Cardiol, 14:127-34, 1989.

17. Kussmaul WG, Smith DL, Herrmann HC, Hirshfeld JW, Laskey WK: Method for

quantification of abnormal right atrial pressure waveforms: application to constrictive

pericarditis. J Invasive Cardiology, 1:213-218, 1989.

18. Herrmann HC, Thibault GE: Patients with atrial fibrillation and flutter admitted to

medical intensive care units. J Intensive Care Medicine, 4:112-116; 1989.

19. Frey M, Berko B, Palevsky H, Hirshfeld JW Jr., Herrmann HC: Recognition of

cardiac tamponade in the presence of severe pulmonary hypertension. Annals Int Med,

111:615-617, 1989.

20. Fifer MA, Molina CR, Giles TD, Herrmann HC, Clement DL, Cody RJ, Cohn JA,

Fowler MB. Hemodynamic and renal effects of atrial natriuretic peptide in congestive

heart failure: Results of a multicenter trial. Am J Cardiol, 65:211-215, 1990.

21. Fifer MA, Aroney CN, Semigran MJ, Herrmann HC, Dec GW, Boucher CA.

Techniques for assessing inotropic effects of drugs in patients with heart failure:

application to the evaluation of nicardipine. Am Heart J, 119:451-456, 1989.

22. Herrmann HC, Kleaveland JP, Hill JA, et al: The M-Heart percutaneous balloon

mitral valvuloplasty registry: Initial results and early follow-up. J Am Coll Cardiol,

15:1221-6, 1990.

23. Herrmann HC, Rosenthal AD, Davis CA. Cardiovascular effects of intracoronary

atrial natriuretic peptide administration in man. Am Heart J 120:308-315, 1990


24. Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J, Murali S,

Herrmann HC, Sandberg JA: Multicenter trial of oral enoximone in patients with

moderate to moderately severe congestive heart failure: Lack of benefit compared to

placebo. Circulation 82:774-80, 1990.

25. Rosenthal AD, Moran M, Herrmann HC. Coronary hemodynamic effects of atrial

natriuretic peptide in man. J Am Coll Cardiol 16:1107-13, 1990.

26. Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW, Herrmann HC, Laskey WK:

Ischemic adaptation during PTCA: Clinical, hemodynamic, and metabolic features.

Circulation 82:2044-51, 1990.

27. Herrmann HC, Hill, JA, Krol J, Kleaveland JP, Pepine CJ. Effectiveness of

percutaneous balloon valvuloplasty in adults with pulmonic valve stenosis. Am. J.

Cardiol. 68:1111-13, 1991.

28. Uricchio FJ, Kussmaul WG, Herrmann HC: Comparison of the effects of load

reduction on left ventricular relaxation in patients with normal and abnormal left

ventricular function. Journal of Applied Cardiology 6:367-378, 1991.

29. Feldman T, Carroll JD, Isner JM, Chisholm RJ, Holmes DR, Massumi GA, Pichard

AD, Herrmann HC, Stertzer SH, O'Neill WW, Dorros G, Sundram P, Bashore TM,

Jones L, Inoue K: Effect of valve deformity on results and mitral regurgitation after

Inoue balloon commissurotomy. Circulation 85:180-187, 1992.

30. Kussmaul WG, Altschuler JA, Herrmann HC, Laskey WK. Effects of pacing

tachycardia and balloon valvuloplasty on pulmonary artery impedance and hydraulic

power in mitral stenosis. Circulation 86:1770-1779, 1992.

31. Vaitkus PM, Herrmann HC, Laskey WL. Management and immediate outcome of

patients with intracoronary thrombus during percutaneous transluminal coronary

angioplasty. Am Heart J., 1992;124:1-8.

32. Semigran MJ, Aroney CN, Herrmann HC, Dec GW, Boucher CA, Fifer MA. Effects

of atrial natriuretic peptide on myocardial contractile and diastolic function in patients

with heart failure. J. Am. Coll. Cardiol., 1992;20:94-97.

33. Herrmann HC, Ramaswamy K, Isner JM, Feldman TE, Carroll JD, Pichard AD,

Bashore TM, Dorros G, Massumi A, Sundram P, Tobias JM, Feldman RC, Ramee S.

Factors influencing immediate results, complications, and short-term followup status

after Inoue balloon mitral valvotomy - A North American multicenter study. Am.

Heart J., 1992;124:160-166.

34. Herrmann HC, Buchbinder M, Clemen MW, Fischman D, Goldberg S, Leon MB,

Schatz RA, Tierstein P, Walker CM, Hirshfeld JW. Emergent use of balloon-

expandable coronary artery stenting for failed PTCA. Circulation, 1992;86:812-819.


35. Matthai WM, Herrmann HC, Kussmaul WG. Failure of endocardial biopsy from the

internal jugular vein due to endocardial scar: a new indication for the femoral venous

approach. Cath and Cardiovasc Diag, 1992;27:289-290.

36. Ziskind AA, Pearce AC, Lemmon CC, Burstein S, Gimple LW, Herrmann HC, McKay

R, Block PC, Waldman H, Palacios IF. Percutaneous balloon pericardial windowing

for the treatment of cardiac tamponade and large pericardial effusions: Description of

technique and report of the first fifty cases. J Am Coll Cardiol, 1993;21:1-5.

37. Dec GW, Fifer MA, Herrmann HC, Cocca-Spoffard D, Semigran MJ. Long-term

outcome of enoximone therapy in patients with refractory heart failure. Am Heart J,

1993;125:423-429.

38. Feldman T, Carroll JD, Herrmann HC, Holmes DR, Bashore TM, Isner JM, Dorros G,

Tobis JM. Effect of balloon size and stepwise inflation techniques on the acute results

of Inoue mitral commissurotomy. Cathet and Cardiovasc Diag, 1993;28:199-205.

39. Laskey WK, Brady ST, Kussmaul WG, Waxler AR, Krol J, Herrmann HC, Hirshfeld

JW, Seghal S. Intravascular ultrasonographic assessment of the results of coronary

artery stenting. Am Heart J, 1993; 125:1576-1583.

40. Marzo KM, Herrmann HC, Mancini D. The effect of balloon mitral valvuloplasty on

exercise capacity, ventilation, and skeletal muscle oxygenation. J Am Coll Cardiol,

1993; 21:856-865.

41. Herrmann HC, Lima JAC, Feldman T, Chisholm R, Isner J, O'Neill W, Ramaswamy

K. Mechanisms and outcome of severe mitral regurgitation after Inoue balloon

valvuloplasty. J Am Coll Cardiol, 1993;22:783-9.

42. Vaitkus P, Mancini D, Herrmann HC. Percutaneous balloon aortic valvuloplasty as a

bridge to cardiac transplantation. J Heart and Lung Transplantation, 1993;6:1062-

1064.

43. Herrmann HC, Feldman TE, Isner JM, Bashore TM, Holmes DR, Rothbaum DA,

Bailey SR, Dorros G. Comparison of results of percutaneous balloon valvuloplasty in

patients with mild and moderate mitral stenosis to those with severe mitral stenosis.

Am J Cardiol, 1993; 71:1300-1303.

44. Kussmaul WG, Krol J, Laskey WK, Herrmann HC, Hirshfeld JW. One-Year Follow-

Up of "Culprit" Versus Multivessel Coronary Angioplasty Trial. Am J Cardiol, 1993;

71:1431-1433.

45. Herrmann HC, Okada SS, Hozakowska, LeVeen RF, Golden MA, Tomaszewski JE,

Weisz PB, Barnathan ES. Inhibition of smooth muscle cell proliferation and

experimental angioplasty restenosis by beta-cyclodextrin tetradecasulfate.

Arteriosclerosis and Thrombosis, 1993;13:924-931.


46. Edmunds LH, Herrmann HC, DiSesa VJ, Ratcliffe MB, Bavaria JE, McCarthy DM.

Left Ventricular Assist Without Thoracotomy: Clinical Experience with the Dennis

Method. Ann Thorac Surg 1994;57:880-5.

47. Semigran MJ, Aroney CN, Herrmann HC, Dec GW, Boucher CA, Fifer MA. Effects

of atrial natriuretic peptide on myocardial contractile and diastolic function in patients

with hypertension. Hypertension, 1994 (in press).

48. Malosky SA, Hirshfeld JWH, Herrmann HC. Comparison of the results of

intracoronary stenting in patients with unstable versus stable angina. Cath and

Cardiovasc Diag., 1994;31:95-101.

49. Feldman T, Herrmann HC, Inoue K. The technique of percutanous transvenous mitral

commissurotomy using the Inoue balloon catheter. Catheterization and Cardiovascular

Diagnosis, 1994; Supplement 2:26-34.

50. Herrmann HC. Acute and chronic efficacy of percutaneous transvenous mitral

commissurotomy: Implications for patient selection. Catheterization and

Cardiovascular Diagnosis, 1994; Supplement 2:61-68.

51. Post JR, Feldman T, Isner J, Herrmann HC. Inoue balloon mitral valvotomy in

patients with severe valvular and subvalvular deformity. J Am Coll Cardiol,

1995;25:1129-1136.

52. Herrmann HC, Malosky SA, Guidera SA, DeAngelo D, Hirshfeld JW. Patient

selection reduces thrombotic complications of emergent stenting for failed PTCA.

Catheterization and Cardiovascular Diagnosis, 1995; 34:286-292.

53. Herrmann HC and Hirshfeld JW. Improving the results of bail-out stenting. Cathet.

and Cardiovasc. Diagnosis, 1995;35:210.

54. Vetrovec GW, Gardin JM, Gregory JJ, Herrmann HC, Rutherford BD, Weiner BH,

Williams RG, Collishaw K, Ganslaw LS. Adult Cardiovascular Physician Resources

and Needs Assessment. J Am Coll Cardiol., 1995;26:1125-32.

55. Vincens J, Temizer D, Post JR, Edmunds LH, Herrmann HC. Long-term outcome of

cardiac surgery in patients with mitral stenosis and severe pulmonary hypertension.

Circulation, 1995;92(Suppl II):II-137-II-142.

56. Savage M, Goldberg S, Bove AA, ..., Herrmann HC, Pepine CJ. Effect of

Thromboxane A2 blockade on clinical outcome and restenosis after successful

coronary angioplasty: M-HEART II. Circulation, 1995;92:3194-3200.

57. Keriakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann

HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V, Sax FL. A randomized,

double-blind, placebo-controlled dose ranging study of Tirofiban (MK-383) platelet


IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J. Am Coll

Cardiol, 1996;27:536-42.

58. Klugherz BD, Kim BK, DeAngelo DL, Herrmann HC, Hirshfeld JW, Kolansky DM.

Three Year Clinical Follow-up After Palmaz-Schatz Stenting. J. Am Coll Cardiol,

1996;27:1185-91.

59. Blitz L, Herrmann HC. Hemodynamic assessment of patients with low flow, low

gradient aortic stenosis. Am J Cardiol, 1996;78:657-668.

60. Mittal S, Berko B, Bavaria J, Herrmann H. Radiation-induced cardiovascular disease.

Am J Cardiol, 1996; 78:114-115.

61. Silvestry FE, Kim B, Pollack BJ, Haimowitz JE, Murray RK, Furth EE, Nisenbaum

HL, Kochman ML, Freedman N, Pine R, Herrmann HC. Cardiac Whipple disease:

identification of Whipple bacillus by electron microscopy in the myocardium of a

patient before death. Annals of Internal Medicine 1997;126:214-216.

62. Mittal S, Weiss D, Kolansky DK, Hirshfeld JW, Herrmann HC. Comparison of

outcome after stenting for de novo versus restenotic narrowings in native coronary

arteries. Am J Cardiol, 1997;80:711-715.

63. Blitz L, Gorman M, Herrmann HC. Results of Aortic Valve Replacement for Aortic

Stenosis With Relatively Low Transvalvular Pressure Gradients. Am J Cardiol,

1998;81:358-362.

64. Klugherz B and Herrmann HC. Mechanical prosthetic valve thrombosis: case report

and review of the literature. J of Thrombosis and Thrombolysis, 1998;6:253-259.

65. Farber LA, Bloch P, Yorke ED, Stevens CW, Herrmann HC, Ruffer JE. A dosimetric

cmparison of conventional vs conformal external beam irradiation of a stented

coronary artery utilizing a new fluoroscopic imaging detector system. Cardiovascular

Radiation Medicine 1999; 1:80-85.

66. Tarka EA, Blitz LA, Herrmann HC. Hemodynamic Effects and Long-Term Outcome

of Percutaneous Balloon Valvuloplasty in Patients With Mitral Stenosis and Atrial

Fibrillation. Clinical Cardiology 2000;23:673-677.

67. Gimple LM, Herrmann HC, Winifred M, and Mammen E. Usefulness of

Subcutaneous Low Molecular Weight Heparin (Ardeparin) for Reduction of

Restenosis After Percutaneous Transluminal Coronary Angioplasty. Am J Cardiol,

1999;83:1524-1529.

68. Mahoney PM, Blitz L, Loh E, Herrmann HC. Hemodynamic Effects of Inhaled Nitric

Oxide in Patients with Mitral Stenosis and Pulmonary Hypertension, Am J Cardiol

2001;87:188-192.


69. Klugherz BD, Meneveau NF, Kolansky DM, Herrmann HC, et al. Predictors of

Clinical Outcome Following Percutaneous Intervention for In-Stent Restenosis, Am J

Cardiol 2000;85:1427-1431.

70. Eagle KA, Guyton RA, Davidoff R, Ewy GA, Fonger J, Gardner TJ, Gott JP,

Herrmann HC, Marlow RA, Nugent W, O’Connor GT, Orszulak TA, Rieselbach RE,

Winters WL, Yusuf S. ACC/AHA guidelines for coronary artery bypass graft surgery:

executive summary and recommendations: a report of the ACC/AHA Task Force on

Practice Guidelines. Circulation. 1999;100:1464-1480.

72. Eagle KA, Guyton RA, Davidoff R, Ewy GA, Fonger J, Gardner TJ, Gott JP,

Herrmann HC, Marlow RA, Nugent W, O’Connor GT, Orszulak TA, Rieselbach RE,

Winters WL, Yusuf S. ACC/AHA guidelines for coronary artery bypass graft surgery:

executive summary and recommendations: a report of the ACC/AHA Task Force on

Practice Guidelines. J Am Coll Cardiol 1999;34:1262-346.

73. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic Effects of Oral

Sildenafil Citrate in Men With Severe Coronary Disease.

New Engl J Med 2000;342:1622-6.

74. Herrmann HC, Moliterno DJ, Ohman EM, Stebbins AL, Bode C, Betriu A, Forycki F,

Miklin JS, Bachinsky WB, Lincoff AM, Califf RM, Topol EJ. Facilitation of Early

Percutaneous Coronary Intervention After Reteplase With or Without Abciximab in

Acute Myocardial Infarction: Results from the SPEED (GUSTO-IV) Pilot) Trial. J

Am Coll Cardiol 2000; 36:1489-1496.

75. Kolansky DM, Blugherz BD, Curran SC, Herrmann HC, Magness K, Wilensky RL,

Hirshfeld JW. Combination Therapy With Clopidogrel and Aspirin After Coronary

Stenting. Cathet Cardiovasc Intervent 2000;50:276-279.

76. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of Two Platelet

Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for Prevention of Ischemic

Events with Percutaneous Coronary Intervention. New Engl J Med 2001;344:1888-94.

77. Herrmann HC, Swierkosz TA, Kapoor S, Tardiff DC, DiBattiste PM, Hirshfeld JW,

Klugherz BD, Kolansky DM, Magness K, Valettas N, Wilensky RL. Comparison of

Degree of Platelet Inhibition by Abciximab-vs-Tirofiban in Patients With Unstable

Angina and Non-Q-Wave Myocardial Infarction Undergoing Percutaneous Coronary

Interventions. Am J Cardiol 2002;89:1293-97.

78. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Wan Y, Aggarwal A, Kabbani SS,

DiBattiste PM. Enhanced Early Inhibition of Platelet Aggregation With an Increased

Bolus of Tirofiban. Am J Cardiol 2002; 90:1421-1423.

79. Roffi M, Moliterno DJ, Meier B, Powers ER, Grines CL, DiBattiste PM, Herrmann

HC, Bertrand M, Harris KE, Demopoulos LA, Topol EJ. Impact of Different Platelet

Glycoprotein IIb/IIIa Receptor Inhibitors Among Diabetic Patients Undergoing


Percutaneous Coronary Intervention: TARGET 1-Year Follow-Up. Circulation

2002;105:2730-2736.

80. Stone GW, Moliterno DJ, Bertrand M, Neumann FJ, Herrmann HC, Powers ER,

Grines CL, Moses JW, Cohen DJ, Cohen EA, Cohen M, Dibattiste PM, Topol EJ.

Impact of Clinical Syndrome Acuity on the Differential Response to Two Glycoprotein

IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting: The TARGET Trial.

Circulation 2002;105:2347-2354.

82. Valettas N, Rho R, Beshai R, Lloyd CT, Ross HT, Kocovic D, Herrmann HC.

Alcohol Septal Ablation Complicated by Complete Heart Block and Permanent

Pacemaker Failure. Cath Cardiovasc Interven 2003;58:189-193.

83. Nguyen CM, Tcheng JE, Aguirre F, Berger PB, Califf RM, Cohen D, Gibson M, Gold

H, Herrmann HC, et al. Pharmacodynamic Considerations with Glycoprotein IIb-IIIa

Receptor Antagonists. J Am Coll Cardiol (submitted).

84. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Lo MW, Yin, KC, Aggarwal A,

Kabbani SS, DiBattiste PM. Increased Concentrations of Tirofiban in Blood and Their

Correlation with Inhibition of Platelet Aggregation After Greater Bolus Doses of

Tirofiban. Am J Card 2003;91:334-336.

85. Maisel AS, Krishnaswamy P, Nowak RM,…,Herrmann HC, McCullough PA. Rapid

Measurement of B-type Natriuretic Peptide in the Emergency Diagnosis of Heart

Failure. N Engl J Med 2002;347:161-7.

86. Herrmann HC. Comparison of Angioplasty with Stenting in Acute Myocardial

Infarction. N Engl J Med 2002;347:367 (letter).

87. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, et al. B-Type

Natriuretic Peptide and Clinical Judgement in Emergency Diagnosis of Heart Failure.

Circulation 2002;106:416-422.

88. Kelley MP, Klugherz BD, Hashemi SM, Meneveau NF, Johnston JM, Matthai WH,

Banka VS, Herrmann HC, et al. One-Year Clinical Outcomes of Protected and

Unprotected Left Main Coronary Artery Stenting. European Heart Journal

2003;24:1554:1559.

89. Moliterno DJ, Yakubov SJ, DiBattiste PM, Herrmann HC, et al. Outcomes at 6

months for the direct comparison of tirofiban and abciximab during percutaneous

coronary revascularization with stent placement: the TARGET follow-up study.

Lancet 2002;360:355-360.

90. Glaser R, Herrmann HC, Murphy SA, Demopoulos LA, DiBattiste PM, Cannon CP,

Braunwald E. Benefit of an early invasive management strategy in women with acute

coronary syndromes. JAMA 2002;288:3124-3129.


91. Ross MJ, Herrmann HC, Moliterno DJ, Blankenship JC, DiBattiste PM, Ellis SG,

Martin JL, White J, Topol EJ. Angiographic Variables Predict Increased Risk for

Adverse Ischemic Events Following Coronary Stenting with Glycoprotein IIb/IIIa

Inhibition: Results from the TARGET Trial. J Am Coll Cardiol, 2003;42:981-88.

92. Ren JF, Marchlinski FE, Callans DJ, Herrmann HC. Clinical Use of AcuNav

Diagnostic Ultrasound Catheter Imaging During Left Heart Radiofrequency Ablation

and Transcatheter Closure Procedures. J Am Soc Echocardiogr 2002;15:1301-8.

93. Juergens CP, White HD, Belardi JA, Macaya C, Soler-Soler J, Meyer BJ, Levy RD,

Bunt T, Menten J, Herrmann HC, Jennifer Adgey AA, Tarnesby G. A Multicenter

Study of the Tolerability of Tirofiban Versus Placebo in Patients Undergoing Planned

Intracoronary Stent Placement. Clinical Therapeutics 2002;24:1332-1344.

94. Maisel AS, McCord J, Nowak RM,…Herrmann HC, McCullough PA. Bedside B-type

Natriuretic Peptide in the Emergency Diagnosis of Heart Failure With Reduced or

Preserved Ejection Fraction: Results From the Breathing Not Properly (BNP)

Multinational Study. J Am Coll Cardiol 2003;41:2010-7.

95. Kereiakes DJ, Szyniszewski AM, Wahr D, Herrmann HC, Simon DI, Rogers C,

Kramer P, et al. A Phase 1 Drug and Light Dose-Escalation Trial of Motexafin

Lutetium Injection and Far Red Light Activation (Photo Angioplasty) in Subjects with

Coronary Artery Disease Undergoing Percutaneous Coronary Intervention and Stent

Deployment: Procedural and Long-Term Results. Circulation 2003;108:1310-1315.

96. Stone GW, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud A, Cambier P,

Caputo R, Turco BM, Kovach R, Brodie B, Herrmann HC, Kuntz RE, Popma JJ,

Ramee S, Cox DA. Randomized Comparison of Distal Protection with a Filter-Based

Catheter and a Balloon Occlusion and Aspiration System During Percutaneous

Intervention of Diseased Saphenous Vein Aorto-Coronary Bypass Grafts. Circulation

2003;108:548-553.

97. McCullough PA, Hollander JE, Nowak RM, Storrow AB, Duc P, Omland T, McCord

J, Herrmann HC, et al. Uncovering Heart Failure in Patients with a History of

Pulmonary Disease: Rationale for the Early Use of B-type Natriuretic Peptide in the

Emergency Department. Acad Emerg Med 2003;10:198-204.

98. McCullough PA, Duc P, Omland T, … Herrmann HC,…Maisel AS. B-Type

Natriuretic Peptide and Renal Function in the Diagnosis of Heart Failure: An Analysis

From the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41:571-

579.

99. Herrmann HC, Murphy SA, DiBattiste PM, DeLucca PT, Demopoulos LA, Gibson

CM, Cannon CP. Greater Benefit of Early Invasive Strategy for Unstable Angina and

Non-ST Elevation Myocardial Infarction in United States Compared With Non-United

States Patients: A TACTICS-TIMI 18 Substudy. Critical Pathways in Cardiology

2004;3:95-100.


100. Ellis SG, Armstrong P, Bertriu A, Brodie B, Herrmann HC, Montalscot G, Neumann

FJ, Smith JJ, Topol EJ. Facilitated Percutaneous Coronary Intervention Versus

Primary PCI: The FINESSE Trial. Am Heart J 2004;147:4:684-692.

101. Maisel AS, Clopton P, Krishnaswamy P,…Herrmann HC, Aumont MC, McCullough

PA. The Impact of Age, Race and Sex on the Ability of BNP to Aid in the Emergency

Diagnosis of Heart Failure: Results from the Breathing Not Properly Multinational

Study. Am Heart J 147(6):1078-1084, 2004.

102. Berger PB, Best PJ, Topol EJ, White J, DiBattiste PM, Chan AW, Kristensen SD,

Herrmann HC, Moliterno DJ. The relation of renal function to ischemic and bleeding

outcomes with 2 different glycoprotein IIb/IIIa inhibitors: The TARGET Trial. Am

Heart J. 2005;149(5):869-75.

103. Herrmann HC, Silvestry FM, Glaser R, See V, Kasner S, Bradbury D, Chang G,

Hirshfeld JW, Horwitz PA, Kelly M. Percutaneous Patent Foramen Ovale and Atrial

Septal Defect Closure in Adults: Results and Device Comparison in 100 Consecutive

Implants at a Single Center. Cath and Cardiovasc Interven 2005;64:197-203.

104. Wu AHB, Omland T, Duc P, …, Herrmann HC, …Maisel AS, McCullough PA.

Effect of Diabetes on B-type Natriuretic Peptide Concentrations in Patients with Acute

Dyspnea: An Analysis from the Breathing Not Properly Multinational Study.

Diabetes Care, 2004;27:2398-2404.

105. Glaser R, Glick HA, Herrmann HC, Kimmel SE. The role of risk stratification in the

decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute

coronary syndromes. J Am Coll Cardiol 2005;47:529-37.

106. Swaminathan A, Stone GW, Rogers C, Hermiller J, Feldman R, Hall P, Haber R,

Masud ARZ, Cambier P, Caputo RP, Cox DA, Mehran R, and Herrmann HC.

Influence of Vessel Diameter on the Efficacy of Distal Protection Devices During

Saphenous Vein Graft Intervention. Am J Cardiol, 2005;95:651-654.

107. Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC,

Herrmann HC, Hillis LD, Hutter AM, Lytle BW, Marlow RA, Nugent WC, Orszulak

TA. ACC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery:

Summary Article, J Am Coll Cardiol 2004;44:1146-54.

108. Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC,

Herrmann HC, Hillis LD, Hutter AM, Lytle BW, Marlow RA, Nugent WC, Orszulak

TA. ACC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery:

Summary Article, Circulation 2004;110:1168-1176.

109. Ilkhanoff L, Naidu SS, Rohatgi S, Ross MJ, Silvestry F, Herrmann HC. Transcatheter

Closure of Interatrial Septal Defects in Patients with Hypoxia. Journal of

Interventional Cardiology 2005;18:227-232.


110. Daniels LB, Clpton P, Bhalla V, …Herrmann HC,…et al. How obesity affects the cut-

points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results

from the Breathing Not Properly Multinational Study. Am Heart J. 2006;151(5):999-

1005.

111. Halkin A, Masud AZ, Rogers C, …, Herrmann HC, Kuntz RE, Popma JJ, Ramee S,

Cox DA, Mehran R, Stone GW. Six-Month Outcomes After Percutaneous

Intervention for Lesions in Aortocoronary Saphenous Vein Grafts Using Distal

Protection Devices: Results from the FIRE Trial. Am Heart J 2006;151:915.e1-

915.e7.

112. Herrmann HC, Levine LA, Macaluso J, Walsh M, Bradbury D, Schwartz S, Mohler

ER, Kimmel SE. A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the

Efficacy of Oral Sildenafil With or Without Atorvastatin in Men with Erectile

Dysfunction Not Initially Responsive to Sildenafil. J Sexual Med 2006;3:303-308.

113. Strunk A, Bhalla V, Clopton P, Nowak RM, McCord J, Hollander JE, Duc P, Storrow AB,

Abraham WT, Wu AHB, Steg G, Perez A, Kazanegra R, Herrmann HC, Aumont MC

McCullough PA, Maisel A. Impact of the History of CHF on the Utility of BNP in the

Emergency Diagnosis of Heart Failure: Results from the Breathing Not Properly (BNP)

Multinational Study. Am J Med 2006:119(1):69.e1-69.e11.

114. Feldman T, Wasserman H, Herrmann HC, et al. Percutaneous Mitral Valve Repair Using

the Edge-to-Edge Technique: 6 Month Results of the EVEREST Phase I Clinical Trial.

J Am Coll Cardiol 2005;46:2134.

115. Mukherjee D, Topol EJ, Bertrand ME, Dalby-Kristensen S, Herrmann HC, et al.

Mortality at 1 Year for the Direct Comparison of Tirofiban and Abciximab During

Percutaneous Coronary Revascularization. Eur Heart J 2005; 26:2524-2528.

116. Kolansky DM, Shah AJ, Mannion T, Glaser R, Hirshfeld JW, Wilensky RL, and

Herrmann HC. FilterWire Distal Embolic Protection Device for Vein Graft Stenting:

Initial Single Center Experience. Clinical Cardiology 2005;28:556-560.

117. Ajay J. Kirtane, Gregory Piazza, Sabina A. Murphy, David A. Morrow, David J.

Cohen, Eric Peterson, Nasser Lakkis, Howard C. Herrmann, Theresa M. Palabrica, C.

Michael Gibson. Correlates of Bleeding Events Among Moderate to High-Risk

Patients Undergoing Percutaneous Coronary Intervention and Treated with

Eptifibatide: Observations from PROTECT – TIMI 30. J Am Coll Cardiol

2006;47:2374-9.

118. Jonas M, Stone GW, Mehran R, Hermiller J, Feldman R, Herrmann HC, Cox DA,

Kuntz RE, Popma JJ, Rogers C. Platelet Glycoprotein IIb/IIIa Receptor Inhibition as

Adjunctive Treatment During Saphenous Vein Graft Stenting: Differential Effects

After Randomization to Occlusion or Filter-Based Embolic Protection. European

Heart Journal 2006; 27: 920-928.


119. Luxenberg DM, Silvestry FM, Herrmann HC, Rohatgi S, Hijazi Z. Use of a New 8Fr

Intracardiac Echocardiographic Catheter to Guide Device of Atrial Septal Defects and

Patient Foramen Ovale in Small Children and Adults: Initial Clinical Experience.

Journal of Invasive Cardiology 2005;17:540-545.

120. Rohatgi S, Wiegers SE, Hsia H, Herling H, Herrmann HC. Acute Decompensation of

Hypertrophic Obstructive Cardiomyopathy Secondary to A-V Dissociation. J Interven

Cardiol 2005;18:1-6.

121. McCord J, Nowak RM, Jacobsen G, …Herrmann HC, Storrow, AB, Abraham WT,

Lamba S, McCullough PA, Maisel A. B-Type Natriuretic Peptide Levels in Patients in

the Emergency Department With Possible Heart Failure and Previous Stable Angina

Pectoris and/or Healed Myocardial Infarction. Am J Cardiol 2005;96:1370-1373.

122. Martin JL, Jia G, Martin SS, Shapiro TA, Herrmann HC, DiBattiste PM, Topol EJ,

Moliterno DJ. The Relationship of Obesity to Ischemic Outcomes Following

Coronary Stent Placement in Contemporary Practice. Catheter Cardiovasc Interv

2006;67:563-570.

123. Foster E, Wasserman H, Gray W, ….Herrmann HC, …Feldman, T. Quantitative

Assessment of Severity of Mitral Regurgitation by Serial Echocardiography in a

Multicenter Clinical Trial of Percutaneous Mitral Valve Repair. Am J Cardiol

2007;100:1557-1583.

124. Herrmann HC, Rohatgi S, Wasserman H, Block P, … Feldman T. Mitral Valve

Hemodynamic Effects of Percutaneous Edge-to-Edge Repair with the MitraClip

Device for Mitral Regurgitation. Catheter Cardiovasc Intervention 2006;68:821-828.

125. Gibson, CM, Karmpaliotis D, Kosmidou I, Murphy SA, Kirtane AJ, Budiu D, Ray KK,

Herrmann HC, Lakkis N, Kovach R, French W, Blankenship J, Lui HH, Palabrica T,

Jennings LK, Cohen DJ, Morrow DA. Comparsion of Effects of Bare Metal Versus

Drug-Eluting Stent Implantation on Biomarker Levels Following Percutaneous

Coronary Intervention for Non-ST-Elevation Acute Coronary Syndrome. Am J

Cardiol 2006;97:1473-77.

126. Ferguson T, Sansing LH, Herrmann HC, Cucchiara B. To close or not to Close? PFO,

Sex, and Cerebrovascular Events. Journal of Invasive Cardiology 2006;18:E292-293.

127. Silvestry FE, Rodriguez L, Herrmann HC, et al. Echocardiographic Guidance and

Assessment of Percutaneous Repair for Mitral Regurgitation with the Evalve

MitraClip: Lessons Learned from Everest 1. J Am Soc Echocardiography 2007;20:

1131-1140.

128. Kalyanasundearam A, Blankenship JC, Berger P, Herrmann HC, McClure R, Moliterno

D. Thrombus Predicts Ischemic Complications During Percutaneous Coronary


Intervention in Saphenous Vein Grafts: Results from TARGET. Cath and Cardiovasc

Interven 2007;69:623-629.

129. Silvestry FE, Naseer N, Wiegers SE, Hirshfeld JW, and Herrmann HC. Percutaneous

Transcatheter Closure of Patent Foramen Ovale with the Amplatzer Cribriform Septal

Occluder. Cath and Cardiovasc Interven 2008;71:383-387.

130. Ellis SG, Tendera M, deBelder MA, ….Herrmann HC, Montalsecot G, Neumann FJ,

Effron MB, Barnathan ES, Topol EJ. Facilitated PCI in Patients with ST-Elevation

Myocardial Infarction. N Engl J Med 2008;358:2205-17.

131. Herrmann HC, Kar S, Siegel R, et al. Effect of Percutaneous Mitral Repair with the

MitraClip Device on Mitral Valve Area and Gradient. EuroIntervention 2008; 4:437-

442

132. Rogers JH, Yeo KK Carroll JD, Cleveland J, Reece TB, Gillinov M, Rodriguez L,

Whitlow P, Woo YJ, Herrmann HC, Young JN. Late Surgical Mitral Valve Repair

After Percutaneous Repair With the MitraClip System. J Cardiovasc Surgery

2009;24:677-81.

133. Silvestry FE, Kerber RE, Brook MM, …Herrmann HC…. Echocardiography-Guided

Interventions (ASE Recommendations for Clinical Practice). J Am Soc Echo

2009;23:213-231.

134. Feldman T, Kar S, Rinaldi M, Fail P, Hermiller J, Smalling R, Whitlow P, Gray W,

Low R, Herrmann HC, Lim S, Foster E, Glower D. Percutaneous Mitral Repair with

the MitraClip Device: Safety and Midterm Durability in the Initial EVEREST Cohort.

J Am Coll Cardiol 2009;54:686-694.

135. Herrmann HC, Lu Jiandong, Brodie BR, et al. Benefit of Facilitated PCI in High-Risk

STEMI Patients Presenting to Nonpercutaneous Coronary Intervention Hospitals.

JACC Intv 2009;2:917-24.

136. Ellis SG, Tenders M, de Bedde M, …Herrmann HC,…Topol EJ. 1-Year Survival in a

Randomized Trial of Facilitated Reperfusion. JACC Intv 2009;2:909-916.

137. Bannan A, Shen R, Silvestry FE, Herrmann HC. Characteristics of Adult Patients with

Atrial Septal Defects Presenting with Paradoxical Embolism. Catheterization and

Cardiovascular Interventions 2009;74:1066-1069.

138. Bui QT, Kolansky DM, Bannan A, Herrmann HC. “Double-Wire” Angio-Seal

Closure Technique After Balloon Aortic Valvuloplasty. Catheterization and

Cardiovascular Interventions 2010;75:488-492.

139. Montelscot G, Ellis SG, DeBelder MA, … Herrmann, HC, …et al. Enoxaparin in

Primary and Facilitated Percutaneous Coronary Intervention: A Formal Prospective


Nonrandomized Substudy of the FINESSE Trial, J Am Coll Cardiol Intv 2010;3:203-

12.

140. Herrmann HC, Baxter S, Ruiz CE, et al. Results of the SCAI Survey of Physicians and

Training Directors on Procedures for Structural and Valvular Heart Disease.

Catheterization and Cardiovascular Interventions 2010;76:E106.

141. Ruiz CE, Feldman TE, Hijazi ZM, Holmes DR, Webb JG, Tuzcu EM, Herrmann H,

Martin GR. Interventional Fellowship in Structural and Congenital Heart Disease for

Adults. Catheterization and Cardiovascular Interventions 2010;76:E90.

142. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers G, Felberg R, Herrmann

H, Kar S, Landzberg M, Raizner A, Wechsler L. Study Design of the CLOSURE

Trial. Stroke 2010;41:_______.

143. Szeto WY, Augoustides JG, Moeller P, McGarvey ML, Walsh E, Desai ND, Bannan

A, Herrmann HC, Bavaria, JE. Cerebral Embolic Exposure During Transfemoral and

Transapical Transcatheter Aortic Valve Implantation. J of Cardiac Surgery 2011;

144. Leon MB, Smith CR, Mack M, et al. Transcatheter Aortic Valve Implantation for

Aortic Stenosis in Patients Who Cannot Undergo Surgery. New Engl J Med

2010;363:1597-1607.

145. Bavaria JE, Szeto W, Roch L, Walsh L, Buckley-Blaskovich V, Solometo L, Burtch K,

Desai N, Herrmann HC. The Progression of a Transcatheter Aortic Valve Program: A

Decision Analysis of Over 680 Patient Referrals. Ann Thorac Surg 2011;92:2072-

2077.

146. Reynolds MR, Magnuson EA, Lei Y, Leon MB, Smith CR, Svensson LG, Webb JG,

Babaliarios VC, Bowers BS, Fearon WF, Herrmann HC, Kapadia S, Kodali SK,

Makkar RR, Pichard AD, Cohen DJ. Health Related Quality of Life After

Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis Who

Cannot Have Surgery. Circulation 2011;124:1964-1972.

147. Siegel RJ, Biner S, Rafique AM, Rinaldi M, Lim S, Fail P, Hermiller J, Smalling R,

Whitlow PL, Herrmann HC, Foster E, Feldman T, Glower D, Kar S. The Acute

Hemodynamic Effects of MitraClip Therapy. J Am Coll Cardiol 2011;57:1658-1665.

148. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM,

Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V,

Thourani V, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN,

Wang D, Pocock SJ. Transcatheter and Surgical Aortic Valve Replacement in High

Risk Patients With Aortic Stenosis. NEJM 2011;364:2187-98.

149. Whitlow PL, Feldman T, Pedersen WR, Lim DS, Kipperman R, Smalling R, Bajwa T,

Herrmann HC, Lasala J, Kramer P, Maddux JT, Tuzcu M, Kapadia S, Trento A, Siegel


RJ, Foster E, Glower D, Kar S. The EVEREST II High Risk Study: Acute and 12

Month Results with Catheter Based Mitral Valve Leaflet Repair. J Am Coll Cardiol

2012:59:130-139.

150. Giri J, …Herrmann, HC. Valve in Valve for Aortic Regurgitation After Balloon

Expandable Transcatheter Aortic Valve Replacement. Catheterization and

Cardiovascular Interventions 2012;80:139-147..

151. Gertz ZM, Raina A, O’Donnell W, Mccauley BD, Shellenberger C, Kolansky DM,

Wilensky RL, Forfia PR, Herrmann HC. Comparison of Invasive and Non-Invasive

Assessment of Aortic Stenosis Severity in the Elderly. Circulation: Cardiovascular

Interventions 2012;5:406-414.

152. Herrmann HC, Gertz ZM, Silvestry FE, Wiegers SE, et al. Effects of Atrial

Fibrillation on Treatment of Mitral Regurgitation in the EVEREST II Randomized

Trial. J Am Coll Cardiol 2012;59:1312-9.

153. Leonardi S, Stebbins A, Lopes RD, Lokhnygina Y, Bhatt DL, Stone GW, Lincoff MA,

Dauerman HL, Gibson CM, White HD, Parick K, Gruberg L, Herrmann HC, McLaurin

BT, Goodman S, Harrington RA, Mahaffey KW. Quantification of Clopidogrel

Effects on Enzymatic Infarct Size Related to PCI in Patients with ACS: Insights from

the CHAMPION PCI trial. Coron Artery Dis. 2013 Jun;24(4):321-7

154. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, Felberg R,

Herrmann HC, Kar S, Landzberg M, Raizner A, Wechsler L. Closure or Medical

Therapy for Cryptogenic Stroke with Patent Foramen Ovale. N Engl J Med

2012;366:991-9.

155. Makkar RR, Fontana GP, Jilaihawi H, … Herrmann HC…Leon MB. Transcatheter

Aortic Valve Replacement for Inoperable Severe Aortic Stenosis. New Engl J Med

2012:366:1696-1704.

156. Marmagkiolis K, Ruiz C, Zajarias A, Bailey SR, Cilingiroglu M, Goldberg SL,

Hakeem A, Herrmann HC, Hijazi ZM, Feldman T. The SCAI Structural Heart Disease

Early Career Task Force survey results. Cathet and Cardiovasc Interventions

2012;80(4):706-711.

157. Laura Mauri, MD, FACC; Elyse Foster, MD, FACC; Donald D. Glower, MD; Patricia

Apruzzese, MS; Joseph M. Massaro, PhD; Howard C. Herrmann, MD, FACC; James

Hermiller, MD, FACC; William Gray, MD, FACC; Andrew Wang, MD, FACC;

Wesley R. Pedersen, MD, FACC; Tanvir Bajwa, MD, FACC; John Lasala, MD, PhD,

FACC; Reginald Low, MD, FACC; Paul Grayburn, MD,FACC; Ted Feldman, MD,

FACC Four-year Results of a Randomized Controlled Trial of Percutaneous Repair

Versus Surgery for Mitral Regurgitation

J Am Coll Cardiol. 2013;62(4):317-328


158. Vergnat M, Levack MM, Jackson BM, Bavaria JE, Herrmann HC, Cheung AT, Weiss

SJ, Gorman JH, Gorman RC. The Effect of Standard and Transcatheter Aortic Valve

Replacement on Mitral Annular Anatomy. Annals of Thoracic Surgery 2013; 95:614-

19.

159. Makkar RR, Jilaihawi H, Chakravarty T, Kapadia S, Babaliaros V, Cheng W, Thourani

V, Fontana G, Bavaria J, Svenson L, Kodali S, Shiota T, Hahn R, Herrmann HC, et al.

Determinants and Outcomes of Acute Transcatheter Valve-in-Valve Therapy or

Embolization: A Study of Multiple Valve Implants in the US PARTNER Trial. J Am

Coll Cardiol 2013;62:418-30.

160. Arnold SV, Spertus JA, Lei Y, Green P, Kirtane AJ, Kapadia S, Thourani VH,

Herrmann HC, Beohar N, Zajarias A, Mack MJ, Leon MB, Cohen DJ. How to Define

a Poor Outcome after Transcatheter Aortic Valve Replacement: Conceptual

Framework and Empirical Observations from the PARTNER Trial. Circ Cardiovasc

Qual Outcomes. 2013;6:

161. Komlo C, Vallabhajosyula P, Bavaria J, Desai ND, Anwaruddin S, Giri J, Herrmann,

HC, Szeto WY. Combined Transaortic and Transcatheter Valve Replacement and

Thoracic Endografting. Annals of Thoracic Surgery 2014;97:696-8.

162. Foster E, Kwan D, Feldman T, … Herrmann HC, Lim S, Glower D. Percutaneous

Mitral Valve Repair in the Initial EVEREST Cohort: Evidence of Reverse Left

Ventricular Remodeling. Circulation: Cardiovascular Imaging 2013; (in press)

163. Herrmann HC, Pibarot P, Hueter I, Gertz ZM, Stewart WJ, Kapadia S, Tuzcu EM,

Babaliaros V, Thourani V, Szeto WY, Bavaria JE, Kodali S, Hahn RT, Williams M,

Miller DC, Douglas PS, Leon MB. Predictors of Mortality and Outcomes of Therapy

in Low Flow Severe Aortic Stenosis – A PARTNER Trial Analysis. Circulation

2013;127:2316-2326.

164. Hahn RT, Pibarot P, Stewart WJ,… Herrmann HC,…Leon M, Douglas PS.

Comparison of Transcatheter and Surgical Aortic Valve Replacement in Severe Aortic

Stenosis: A Longitudinal Study of Echo Parameters in Cohort A of the PARTNER

Trial. J Am Coll Cardiol 2013;61:2514.

165. Beohar N, Zajarias A, Thourani VH, Herrmann HC, Mack M, Kapadia S, Green P,

Arnold S, Cohen DJ, Xu K, Leon MB, Kirtane AJ. Analysis of Early Mortality After

TAVR Among Patients Successfully Discharged From the Hospital and Alive at 30

Days: An Outcomes Based “Futility” Assessment from the PARTNER Trial. Am J

Cardiol. 2014 Aug 27. pii: S0002-9149(14)01715-9.

166. Svenson LG, Blackstone EH, Rajeswaran J,…, Herrmann, HC, and Akin JJ,.

Comprehensive Analysis of Mortality Among Patients Undergoing TAVR. J Am Coll

Cardiol 2014;64:158-68.


167. Makkar RR, Jilaihawi H, Mack M, …Herrmann HC…Leon M. Stratification of

Outcomes After TAVR According to Inoperability by Technical or Clinical Criteria. J

Am Coll Cardiol 2014;63:901-911

168. Okada D, Rahmouni HW, Herrmann HC, Bavaria JE, Forfia PR, Han Y. Assessment

of Right Ventricular Function by Transthoracic Echocardiography Following Aortic

Valve Replacement. Echocardiography 2014;31:552-7.

169. Lim DS, Reynolds MR, Feldman T, Kar S, Herrmann HC, Wang A, Whitlow PL, Gray

WA, Grayburn P, Mack MJ, Glower D. Improved Functional Status and Quality of

Life in Prohibitive Surgical Risk Patients With Degenerative MR After Transcatheter

Mitral Valve Repair. J Am Coll Cardiol. 2014;64:182-92.

170. Szerlip M, Tokunbo Adeniyi, Rebeca J Kim, Vinod Thourani, Vasilis

Babaliaros, Joseph Bavaria, Howard C Herrmann, Raj Makkar, Tarun Chakravarty,

Joshua Rovin, Don Creighton, Craig Miller, Kim Baio, Lisa Walsh, Jasmina Katinic,

Rebecca Letterer, Leigh Trautman, Morley Herbert, Robert Farkas, Jill Fowler, David

Brown, Elizabeth Holper, Michael Mack. The Outcomes of TAVR in Patients with

End Stage Renal Disease. Cath and Cardiovasc Interv 2016;

171. Hahn RT, Pibarot P, Webb J, Rodes-Cabau J, Herrmann HC, Williams M, et al.

Outcomes with Post-Dilatation Following Transcatheter Aortic Valve Replacement. J

Am Coll Cardiol Cardiovasc Interv 2014;7:781-9.

172. Fearon WF, Kodali S, Doshi D, Fischbein MP, Yeung AC, Tuzcu EM, Rihal CS,

Babaliaros V, Zajarias A, Herrmann HC, Brown DL, Mack M, Teirstein PS,

Whisenant BK, Makkar R, Kapadia S, Leon MB. Outcomes After Transfemoral

Transcatheter Aortic Valve Replacement. JACC Cardiovascular Interv 2014;7:1245-

51.

173. McCarthy F, Desai N, Herrmann HC, Kolbrin D, Vallabhajosyula P, Fox Z, Menon R,

Walsh L, Augoustides J, Giri J, Anwaruddin S, Li R, Jagasia D, Bavaria J, Szeto W.

Propensity-Matched Comparison of Open Aortic and Mitral Replacement or Repair

Versus Transcatheter Aortic Valve Replacement in Patients With Significant Mitral

Regurgitation. Annals of Thorac Surg 2014;98:1267-73.

174. Rylski B, Szeto WY, Bavaria J, Walsh E, Anwaruddin S, Desai ND, Moser W,

Herrmann HC, Milewski RK. Transcatheter Aortic Valve Implantation in Patients

with Ascending Aortic Dilatation: the Procedure’s Safety and Mid-Term Follow-Up.

Eur J Cardiothorac Surg 2014;46:228-33.

175. Beohar N, et al. The relative performance characteristics of the Logistic EuroSCORE

and the Society of Thoracic Surgery score in the PARTNER Trial. J Thorac

Cardiovasc Surgery 2014 Apr 13.

176. Kadakia M, Herrmann HC, Desai ND, Fox Z, Ogbara J, Anwaruddin S, Jagasia D,

Bavaria JE, Szeto WY, Vallabhajosyula P, Li R, Menon R, Kobrin DM, Giri J. Factors


Associated with Vascular Complications in Patients Undergoing Balloon-Expandable

Transfemoral Transcatheter Aortic Valve Replacement via Open Versus Percutaneous

Approaches. Circ Cardiovasc Interv 2014;7:570-6.

177. Gertz ZM, McCauley BD, Raina A, O’Donnell W, Shellenberger C., Willhide J, Forfia

PR, Herrmann HC. Estimation of Oxygen Consumption in Elderly Patients With

Aortic Stenosis. Catheter Cardiovasc Interv 2014;83(1):E128-33.

178. O’Neill B, Guerrero M, Thourani VH, et al. Prognostic value of serial BNP

measurement in TAVR (from the PARTNER Trial). Am J Cardiol 2015;115:1265-72.

179. Wang A, Sangli C, Ailawadi G, Kar S, Herrmann HC, Grayburn P, Foster E,

Weissman N, Glower D, Feldman T. Evaluation of renal function before and after

percutaneous mitral valve repair. Circulation Cardiovasc Interv 2015;8(1):

180. Shreenivas SS, Lilly SM, Szeto WY…and Herrmann HC. Circulatory support is

associated with higher short and long term mortality after transcatheter aortic valve

replacement: A PARTNER Trial substudy. Cath and Cardiovasc Interv 2015;86:316-

22.

181. Silvestry FE, Kadakia MB, Willhide J, and Herrmann HC. Initial experience with a

novel real-time 3D intracardiac ultrasound system to guide percutaneous cardiac

structural interventions. J Am Soc Echo 2014;27:978-83.

182. Kadakia M, Frank E. Silvestry, Nimesh Desai, Saif Anwaruddin, Jay Giri, Wilson

Szeto, and Howard C. Herrmann. Feasibility of Volumetric Intracardiac

Echocardiography to Facilitate Transcatheter Aortic Valve Replacement. J Invasive

Cardiology 2014 (submitted).

183. Marcantuono R, Gutsche J, Burke-Julien M, Anwaruddin S, Giri J, Szeto W,

Vallybohousyla P, Bavaria J, Walsh L, Jones D. Cantwell C, McGrath J, DiBiase L,

McCool S, Mangiano-Blanchard L, Augustides Y, Patel P, Weiss S, Stetson R,

Herrmann HC. Rationale, Development, and Initial Results of a Fast Track Protocol

for Transfemoral Transcatheter Aortic Valve Replacement. Cath and Cardiovasc

Interv 2014 (in press).

184. Pibarot P, Weissman N, Stewart W,…Herrmann HC…Leon M. Incidence and

Sequelae of Prosthesis-Patient Mismatch in Transcatheter versus Surgical Valve

Replacement in High-Risk Patients with Severe Aortic Stenosis - A PARTNER Trial

Cohort A Analysis. J Am Coll Cardiol 2014;64:1323-34.

185. Shah AM, Ogbara J, Herrmann HC, et al. Outcomes of transcatheter aortic valve

replacement in patients with chronic liver disease. CCI 2015;86:888-894.

186. Chen J, Nawaz N, Fox Z, Komlo C, Anwaruddin S, Desai N, Jagasia D, Herrmann

HC, Han Y. Echocardiographic determinants of LV functional improvement after

TAVR. Catheterization and Cardiovascular Interventions 2016;87:1164-72.


187. Nazif T, Dizon J, Hahn RT, Xu K, Babaliaros V, Douglas PS, El-Chami MF,

Herrmann HC, Hess PL, … Kodali S. Predictors and Clinical Outcomes of Permanent

Pacemaker Implantation After Transcatheter Aortic Valve Replacement. J Am Coll

Cardiol: Cardiovasc Interv. 2015;8:60-9.

188. Kapadia S, Agarwal S, Miller C, Webb J, Mack M, Ellis S, Herrmann HC, Pichard A,

Tuzcu EM, Svensson L, Smith C, Rajeswaran J, Kodali S, Makkar R, Thourani V,

Blackstone E, Leon M. Insights Into Timing, Risk Factors, and Outcomes of Stroke

and Transient Ischemic Attack After Transcatheter Aortic Valve Replacement in the

PARTNER Trial (Placement of Aortic Transcatheter Valves). Circulation

Cardiovascular Interventions 2016; 2016;9:e002981.

189. Amat-Santos, IJ, Messika-Zeitoun D, Eltchaninoff H,…Herrmann HC,…Rodes-Cabau

J. Infective Endocarditis Following Transcatheter Aortic Valve Implantation: Results

from a Large Multicenter Registry. Circulation 2015;131:1566-1574.

190. Liyanage L, Lee N, Cook T, Litt H, Herrmann HC, Jagasia D, Han Y. The impact of

gender on cardiovascular system calcification in very elderly patients with severe

aortic stenosis. 2014 (submitted).

191. Raina A, Gertz ZM, O’Donnell WT, Herrmann HC, Forfia PR. Pulmonary

hypertension is a manifestation of congestive heart failure and left ventricular diastolic

dysfunction in octogenarians with severe aortic stenosis. Pulmonary Circulation

2015;5:521-526.

192. Kapadia SR, Tuzcu EM, Makkar RR, Svensson LG, Agarwal S, Kodali S, Fontana GP,

We bb JG, Mack M, Thourani VH, Babaliaros VC, Herrmann HC, Szeto W, Pichard

AD,Williams MR, Anderson WN, Akin JJ, Miller DC, Smith CR, Leon MB. Long-

Term Outcomes of Inoperable Patients with Aortic Stenosis Randomized to

Transcatheter Aortic Valve Replacement or Standard Therapy. Circulation.

2014;130:1483-1492.

193. DeBacker O, Piazza N, Banai S, Lutter G, Maisano F, Herrmann HC, Franzen OW,

Sondergaard L. Percutaneous transcatheter mitral valve replacement: an overview of

devices in preclinical and early clinical evaluation. Circ Cardiovasc Interv.

2014;7:400-9.

194. Chatterjee S, Herrmann HC, Wilensky RL, Hirshfeld J, McCormick D, Frankel DS,

Yeh RW, Armstrong EJ, Kumbhani DJ, Giri J. Safety of left atrial appendage

exclusion with the Lariat device: A systematic review of published reports and analytic

review of the FDA MAUDE database. JAMA Internal Medicine 2015;175:1104-9.

195. Thourani V, Babaliaros V, Kodali S, …Herrmann HC,…Smith C. Three-Year

Outcomes from the PARTNER Trial in High-Risk Patients with Aortic Stenosis

Treated with Transcatheter or Surgical Aortic Valve Replacement. Circulation 2014

(in press).


196. Kapadia SR, Leon MB, Makkar RR, Tuzcu EM, Svensson LG, Kodali S, Webb JG,

Mack M, Douglas P, Thourani VH, Babaliaros VC, Herrmann HC, Szeto WY, Pichard

AD, Williams MR, Fontana GP, Miller DC, Anderson WN, Akin JJ, Smith CR. Five-

year outcomes of TAVR compared with standard treatment for patients inoperable

aortic stenosis (PARTNER 1): a randomized controlled trial. Lancet 2015;385:2485-

91.

197. Mack M, Leon M, Smith, Miller DC,…Herrmann HC,…Svensson LG. Five-year

outcomes of TAVR or surgical AVR for high surgical risk patients with aortic stenosis

(PARTNER 1): a randomized controlled trial. Lancet 2015; 385: 2477-84.

198. Kobrin DM, McCarthy FH, Herrmann HC, Anwaruddin S, Kobrin S, Szeto WY,

Bavaria JE, Groenveld PW, Desai ND. Dialysis patients undergoing transcatheter

aortic valve replacement in the United States: A propensity matched comparison.

Annals of Thoracic Surgery 2015 (submitted).

199. Thourani VH, Jensen HA, Babaliaros V, et al. Outcomes in nonagenarians Undergoing

TAVR in the PARTNER-1 Trial. Annals of Surgery 2015 (in press).

200. Amat-Santos IJ., David Messika-Zeitoun D, Eltchaninoff H, et al. Infective

Endocarditis Following Transcatheter Aortic Valve Implantation: Results from a Large

Multicenter Registry. Circulation 2015;131 (18): 1566-74.

201. Livanage L, Lee NJ, cook T, Herrmann HC, Jagasia D, Litt H, Han Y. Impact of Sex

on Cardiovascular System Calcification in Very Elderly Patients with Severe Aortic

Stenosis. International Journal of Cardiovascular Imaging 2015 (submitted).

202. Dizon JM, Nazif TM, Hess PL…Herrmann HC…Smith CR, Leon MB, Kodali S.

Chronic Pacing and Adverse Outcomes After TAVI. Heart 2015; 10.1136/heartjnl-

2015-307666

203. McCarthy FH, McDermott KM, Bavaria JE, Kini V, Herrmann HC, Anwaruddin S,

Giri J, Szeto WY, Groeneveld PW, Desai ND. Comparative Economics of

Transcatheter and Surgical Aortic Valve Replacments in Medicare Patients. 2015

(submitted).

204. Webb JG, Doshi D, Mack MJ…Herrmann HC…Leon MB. A Randomized Evaluation

of the SAPIEN XT Transcatheter Heart Valve System in Patients with Aortic Stenosis

Who Are Not Candidates for Surgery. JACC Cardiovasc Interv 2015;8:1797-806.

205. Kobrin DM, McCarthy FH, Herrmann HC, Anwaruddin S, Kobrin S, Szeto WY,

Bavaria JE, Groeneveld PW, Desai ND. Transcatheter and Surgical Aortic Valve

Replacement in Dialysis Patients: A Propensity-Matched Comparison. Ann Thorac

Surg. 2015 Aug 11.


206. Thourani VH, Jensen HA, O’Neill B, …Herrmann HC….Leon MB. Prognostic value

of B-type natriuretic peptide on mortality in transapical aortic valve replacement:

Results from the Partner trial. 2016 (submitted).

207. Feldman T, Kar S, Elmariah S, Smart SC…Herrmann HC, Acker MA, Silvestry FE,

Foster E, Wang A, Glower DD, Mauri L. Randomized Comparison of Percutaneous

Repair and Surgery for Mitral Regurgitation – 5 Year Results of EVEREST II. J Am

Coll Cardiol 2015;66:2844-54.

208. Anjan V, Herrmann HC, Pibarot P, et al. Effects and time course of improvement in

flow after TAVR in patients with low flow aortic stenosis – A Partner trial substudy.

JAMA Cardiology 2016;1(15):584-592.

209. Herrmann HC, Thourani VH, Kodali SK, et al. One-year clinical outcomes with

Sapien 3 TAVR in High Risk and Inoperable Patients with Severe Aortic Stenosis.

Circulation 2016;134:130-140.

210. Thourani VH, Forcillo J, Beohar N, et al. Impact of Preoperative Chronic Kidney

Disease in 2,531 High- and Extreme-Risk Patients Undergoing Transcatheter Aortic

Valve Replacement in the PARTNER-1 Trial. Annals of Thoracic Surgery 2016

(submitted)

211. Leon MB, Smith, CR, Mack MJ, Makkar RR,…Herrmann HC,…Webb JG.

Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients. N

Eng J Med 2016;374:1609-20.

212. Thourani VH, Kodali S, Makkar RR, Herrmann HC, et al. SAPIEN 3 transcatheter

aortic valve replacement versus surgery in intermediate risk patients. Lancet 2016;

published on line April 3, 2016.

213. Pibarot P, Hahn R, Weissman N, Herrmann H, Thourani V, Kodali S. Impact of

paravalvular regurgitation assessed by 5-class grading scheme on 1-year outcomes in

the PARTNER-II SAPIEN 3 high risk/inoperable cohort. (manuscript in preparation).

214. Don CW, Johnson A, Burke C,…Herrmann HC,…Reisman M. TAVR age paradox:

the oldest patients have better than expected outcomes in the PARTNER study.

(manuscript in preparation).

215. Kodali S, Thourani VH, White J, …Herrmann HC,…Leon MB. Early clinical and

echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in

inoperable, high-risk and intermediate-risk patients with aortic stenosis. European

Heart Journal Advance Access published March 31, 2016.

216. Wang J, Kondapally YR, Jagasia D, Fletcher E, Herrmann HC, Han Y. Comparison of

Non-Contrast Cardiovascular Magnetic Resonance and Computed Tomography

Angiography for Aortic Annular Sizing for Transcatheter Aortic Valve Replacement.

2016 (submitted).


217. Baron SJ, Arnold SV, Herrmann HC, et al. Impact of Ejection Fraction and Aortic

Valve Gradient on Outcomes of TAVR. J Am Coll Cardiol 2016;67:2349-58.

218. McCarthy FH, Spragan DD, Savino D, …Herrmann HC,…Desai ND. Outcomes,

Readmissions and Costs in Transfemoral and Alterative Access Transcatheter Aortic

Valve Replacement in the U.S. Medicare Population 2016 (submitted).

219. Yahagi K, Ladich E, Kutys R,…Herrmann HC,… Finn AV. Pathology of Balloon-

Expandable Transcatheter Aortic Valves. 2016 (submitted).

220. Regueiro A, Linke A, Latib A, Ihlemann N, Urena M, Walther T, Husser O, Herrmann

HC, et al. Association between transcatheter aortic valve replacement and subsequent

infective endocarditis and in-hospital death. J Am Med Assoc 2016;316:1083-1092.

221. Hyman MC, Vemulapalli S, Szeto W, … Herrmann HC… Giri J. Moderate sedation

versus general anesthesia for TAVR: Insights from the NCDR STS/ACCT TVT

registry. 2016; submitted for publication.

222. Webb JG, Mack MJ, Dvir D, White JM, Herrmann HC, et al. Transcatheter Valve-in-

Valve Implantation for Bioprosthetic Aortic Valve Degeneration – Results from the

PARTNER II Valve-in-Valve Registry. J Am Coll Cardiol 2016; (In press).

223. McCarthy FH, Vemulapalli S, Li Z, …Herrmann HC, Bavaria JE, Szeto WY. The

impact of tricuspid regurgitation on TAVR outcomes: a report from the STS/ACC

TVT registry. 2017 (submitted).

224. Douglas et al. Mid-Term Hemodynamics of Transcatheter and Surgical Aortic Valves

in the Placement of AoRTic TraNscathetER Valve Trial (PARTNER) Trial 2017

(submitted).

225. Dvir et al, Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses:

Insights from the PARTNER II Valve-in-Valve Registry on Utilizing Baseline

Computed-Tomographic Assessment 2017 (submitted).

226. Genereux e t al. Classification of AS based on the extent of cardiac damage. 2017

(submitted).

227. Thourani VH, Forcillo J, Szeto WY, …Herrmann HC…Mack MJ. Clinical and

Echocardiographic Outcomes in 937 Intermediate-Risk Patients Undergoing Surgical

Aortic Valve Replacement from the PARTNER 2A Study. Annals of Thoracic Surgery

2017 (submitted).

228. Don CW, et al. The TAVR Age Paradox. JAMA 2017 (submitted).

229. Anwaruddin S, Kirtane A, Thourani V, Vemulapalli S, Manandhar P, Matsuioaka R,

Desai ND, Herrmann HC, Jagasia D, Bavaria JE, Giri J, Vallabhajosyula P, McCarthy


F, Szeto W. Characterizing Paravalvular Regurgitation after TAVR: AStudy of the

STS/ACC TVT registry. JACC Cardiovasc Intv 2017 (in press).


Editorials, Reviews, Case Reports, and Chapters:

1. Herrmann, HC. Balloon mitral valvuloplasty: Better therapy for mitral stenosis.

Internal Medicine 13:19-29, 1992.

2. Shapiro TA, Herrmann HC. Coronary angiography and interventional cardiology.

Current Opinion in Radiology, 1992; 4:55-64.

3. Weisz PB, Herrmann HC, Joullie MM, Kumor K, Levine E, Macarak EJ, Weiner D.

Angiogenesis and heparin mimics, in: Steiner R, Weisz P., Langer R, (eds.):

Angiogenesis: Key principles, Birkhauser Verlag, Basel, Switzerland; 1992: pp. 107-

117.

4. Herrmann, HC and Hill, JA. Balloon Valvuloplasty: Indications, techniques, and

results, in Diagnostic and Therapeutic Cardiac Catheterization, 2nd Edition, Pepine,

CJ, Hill JA, Lambert CR, eds., Williams and Wilkins, Baltimore, MD, 1993, pp. 593-

612.

5. Hirshfeld JW, Herrmann HC. Stent deployment: technical considerations, in Clinical

use of the Palmaz-Schatz balloon-expandable stent, Herrmann HC and Hirshfeld JW,

eds., Futura Publishing Co., Inc., Mount Kisco, New York, 1993; pp. 23-42.

6. Herrmann HC, Hirshfeld JW. Emergent stenting for failed PTCA, in Clinical use of

the Palmaz-Schatz balloon-expandable stent, Herrmann HC and Hirshfeld JW, eds.,

Futura Publishing Co., Inc., Mount Kisco, New York, 1993; pp. 93-109.

7. Vaitkus PV, Herrmann HC, LeWinter ML. Management of malignant pericardial

effusions: an update, J Am Med Assoc., 1994;272:59-64.

8. Herrmann HC. Top 10 reasons to use the Inoue balloon. Cath and Cardiovasc Diag,

1996; 38:15.

9. Herrmann HC, Hirshfeld JW. Coronary angioplasty and related techniques, in

Abram's Angiography, Baum, S and Pentecost MJ, eds., Little, Brown and Co.,

Boston, 1997, vol. III, pp. 366-385.

10. Hirshfeld, JW, Herrmann HC. The Palmaz-Schatz Coronary Stent, in Intracoronary

Stents, Roubin G., editor. 1996, (in press).

11. Herrmann HC. Mitral, Pulmonic, Tricuspid, and Prosthetic Valve Disease, in Uretsky

B, Diagnositic Cardiac Catheterization, Blackwell Science Inc., Malden, MA, 1997,

pp. 375-396.

12. Kumar A and Herrmann HC. Tirofiban, An investigational glycoprotien IIb/IIIa

receptor antagonist. Exp. Opin. Invest. Drugs 1997;6:1257-1267.


13. Herrmann HC. Balloon valvuloplasty: Indications, techniques, and results, in

Diagnostic and Therapeutic Cardiac Catheterization, 3rd Edition, Pepine, CJ, Hill JA,

Lambert CR, eds., Williams and Wilkins, Baltimore, MD, 1998, pp. 764-785.

14. Herrmann, HC. New laser surgery for angina, HealthNews, 1997;3:3-4.

15. Herrmann, HC. Best Treatment for Silent Ischemia, Heart Watch, 1997;1:4.

16. Herrmann, HC. Can Vitamin E Pills Protect the Heart?, Heart Watch, 1997;1-2:3.

17. Herrmann, HC. FDA Panel Rejects Laser Surgery, Heart Watch, 1997;1-3:3.

18. Herrmann, HC. Complications and Long-Term Results of Percutaneous Balloon

Valvuloplasty for Mitral Stenosis. Cathet Cardiovasc Diagnosis, 1998;43: 140.

19. Mittal S and Herrmann, HC. Stenting for De Novo Versus Restenotic Coronary

Arteries. Cardiology Review, 1998;15:35-38.

20. Herrmann, HC. Angioplasty vs. Drugs for Angina, Heart Watch, December, 1997, p. 3.

21. Herrmann, HC. Rethinking Obesity, Heart Watch, 1998;2:4

22. Herrmann, HC. Repairing a Blocked Heart Valve, Heart Watch, 1998;2:2.

23. Herrmann, HC. Exercise Testing After Bypass, Heart Watch, 1998;2:4.

24. Herrmann, HC. Choosing Between Bypass and Angioplasty, Heart Watch, 1998;21-2.

25. Herrmann, HC. Aspirin and ACE Inhibitors, Heart Watch, 1999;3:1-2.

26. Herrmann, HC. Aortic Sclerosis: A Sign of Trouble, 1999;43:4.

27. Li RH, Herrmann HC. Facilitation of Early Coronary Intervention by Abciximab and

Reduced-Dose Reteplase in Acute Myocardial Infarction: A Case Report. J Invasive

Cardiology, 1999;1:7.

28. Liang BT, Swierkosz T, Herrmann HC, Kimmel S, and Jacobson KA. Adenosine and

Ischemic Preconditioning. Current Pharmaceutical Design. 1999;5:1029-1041.

29. Herrmann HC. Tirofiban – An Overview of the Phase III Trials. J Invasive

Cardiology. 1999;11 (Suppl C): 7C-13C.

30. Herrmann HC. New Approaches to Revascularization in Acute Myocardial Infarction

and Stroke: Introduction. Am J Cardiol 2000;85:1C.


31. Herrmann HC. Triple Therapy for Acute Myocardial Infarction: Combining

Fibrinolysis, Platelet IIb/IIIa Inhibition, and Percutaneous Coronary Intervention. Am

J Cardiol 2000;85:10C-16C.

32. Mahoney P, Herrmann HC. Anticoagulation Before and After Percutaneous Balloon

Valvuloplasty. J Interventional Card. 2000;13:389-394.

33. Li RH, Herrmann HC. Facilitated PCI: A Novel Concept in Expediting and Improving

AMI Care. Am Heart J 2000;140:S125-S135.

34. Herrmann HC. Hemodynamic Effects of Sildenafil. N Eng J Med 2000;343:967-977

(letter).

35. Swierkosz TA, Valettas N, Herrmann HC. IIb or Not IIb: When, How, and Which

GP IIb/IIIa Inhibitor? Cath and Cardiovasc Interven 2001;52:433-434.

36. McCauley K, Lloyd C, Herrmann HC, Pavri BB. Vasospasm-Induced Heart Block, J

Cardiovasc Nursing 2001;15:105-108.

37. Herrmann HC, Kelley MP, Ellis SG. Facilitated PCI: Rationale and Design of the

FINESSE Trial. J Inv Cardiol 2001;13 (suppl A) : 10A-15A.

38. Chang G and Herrmann HC. Issues and Recommendations for Treating Erectile

Dysfunction in Men with Ischemic Heart Disease. Cardio Vasc Reviews and Reports

2001;22:285-291.

39. Herrmann HC, Li RH, Ohman EM. Facilitated Percutaneous Coronary Intervention:

Results from the SPEED Trial. Eur Heart J 2001;3 (Suppl A): A26-A34.

40. Chew DP, Moliterno DJ, Herrmann HC. Present and Potential Future Paradigms for

the Treatment of ST-Segment-Elevation Acute Myocardial Infarction. J Inv Cardiol

2002;14:3A-20A.

41. Glaser R, Herrmann HC. Does Primary Stent Implantation Increase Late Mortality

After Myocardial Infarction? Cath Cardiovasc Interventions 2001;54:333-334.

42. Glaser R, Herrmann HC. Early, Rescue and Facilitated Percutaneous Coronary

Intervention for Acute Myocardial Infarction. ACC Current Journal Review

2001;10:62-66.

43. Valettas, N and Herrmann HC. “Tirofiban in Interventional Cardiology,” in Platelet

Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease, Lincoff, AM, ed., Humana

Press, 2003: pp. 147-166.

44. Rohatgi S and Herrmann HC. “Safety and Hemodynamic Effects of Sildenafil in

Patients With Coronary Artery Disease,” in Heart Disease and Erectile Dysfunction, R.

Kloner, ed., Humana Press, 2004, pp. 179-193.


45. Wiegers SE, Herrmann HC, Plappert T, St. John Sutton M. “Valvular Heart Disease,”

in Clinical Cardiovascular Imaging, A Companion to Braunwald’s Heart Disease, St.

John Sutton MG and Rutherford JD, editors, Elsevier Saunders, Philadelphia, 2004,

pp. 280-338.

46. Valettas N and Herrmann HC. The Role of Platelets and Platelet Inhibition in Acute

Myocardial Infarction. Coronary Artery Disease 2003;14:357-363.

47. Glaser R and Herrmann HC. Commentary on Long-Term Outcome of FRISC II. J of

Evidence-Based Cardiovascular Medicine 2003;7:70-72.

48. Herrmann HC. Optimizing Outcomes in Acute ST-Elevation Myocardial Infarction. J

Am Coll Cardiol 2003 (editorial comment); 42:1357-1359.

49. Herrmann HC. Prevention of Cardiovascular Events After Percutaneous Coronary

Intervention. New Engl J Med 2004;350:2708-2710.

50. Glaser R and Herrmann HC. Safety of Vascular Closure Devices – Are Women

Different? Journal of Invasive Cardiology 2004 (in press).

51. Herrmann HC. Percutaneous Valve Repair and Replacement. Journal of Invasive

Cardiology 2004;16: 59S-64S.

52. Herrmann HC. The Bifurcation Stent, commentary, Journal of Invasive Cardiology

2004; 16:436-438.

53. Naidu SS, Rohatgi S, Herrmann HC, Glaser R. Unprotected Left Main “Kissing”

Stent Implantation With a Percutaneous Ventricular Assist Device. J Invasive

Cardiology 2004;16:683-684.

54. Rohatgi S, Rajagopalan S, Herrmann HC. Management of Vasculogenic Impotence in

Manual of Vascular Diseases, Rajagopalan S, Mukherjee D, and Mohler ER, eds.,

Lippincott Williams and Williams, Philadelphia, 2005, pp. 336-352.

55. Herrmann HC. Transfer for Primary Angioplasty – The Importance of Time.

Circulation 2005;111:718-720.

56. St. Goar F, Fann JI, Feldman TE, Block PC, Herrmann HC. Percutaneous Mitral

Valve Repair with the Edge-to-Edge Technique in Interventional Cardiology:

Percutaneous Noncoronary Intervention, Herrmann HC, editor, Humana Press,

Totowa, NJ 2005; pp. 87-96.

57. Rohatgi S, Herrmann HC, Hirshfeld JW, Percutaneous Coronary Intervention and

Related Techniques, in Abram's Angiography, Fifth Edition, Baum, S and Pentecost

MJ, eds., Little, Brown and Co., Boston, 2006: pp. 470-485.


58. Herrmann HC. Percutaneous Valve Therapies. Current Treatment Options in

Cardiovascular Medicine 2005;7:477-482.

59. Herrmann HC. ICE-Guided Percutaneous Non-Coronary Interventional Procedures in

Intracardiac Echocardiography, Silvestry FE and Wiegers SE, eds., Taylor and Francis

Press, Boca Raton, FL, 2006:75-90.

60. Feldman T, Herrmann HC, St. Goar F. Percutaneous Treatment of Valvular Heart

Disease: Catheter Based Aortic Valve Replacement and Mitral Valve Repair

Therapies. Am J Geriatric Cardiology 2006;15:291-301.

61. Herrmann HC and Feldman T. Percutaneous Mitral Valve Edge-to-Edge Repair With

the Evalve MitraClip System: Rationale and Phase 1 Results. EuroIntervention

2006;1 (supplement A): A36-A39.

62. Makkar K, Wilensky RL, Burke-Julien M, Herrmann HC, Spinler SA. Rash with Both

Clopidogrel and Ticlopidine in Two Patients Following PCI With DES. The Annals of

Pharmacotherapy 2006;40:1204-1207.

63. Mejia V, Woo YJ, Herrmann HC. Left Main Coronary Embolism. J Invasive

Cardiology 2006;18:296.

64. Herrmann HC. Book Review: Transcatheter Valve Repair. Circulation 2006;114:12.

65. Herrmann HC. Update and Rationale for Ongoing Acute MI Trials: Combination

Therapy, Facilitation, and Myocardial Preservation. Am Heart J 2006;151:S30-S39.

66. Herrmann HC. Patent Foramen Ovale and Atrial Septal Defect in Interventional

Cardiology 900 Questions: An Interventional Cardiology Board Review, Mukherjee D,

Cho L, Moliterno DJ, Gilbreath DA, eds, 2007, Wolters Kluwer Publisher, pp 254-

262.

67. Glaser R and Herrmann HC. PCI in African-Americans: Closing the “Gender Gap.”

Journal of Invasive Cardiology, (editorial) 2007:19:129-130.

68. Mejia V, Naidu H, and Herrmann HC. Percutaneous Support for High Risk PCI, in

Interventional Cardiology, EJ Topol, editor, Elsevier Press, 2008, pp. 641-653.

69. Reddy K and Herrmann HC. “Role of Facilitated PCI in STEMI,” in Clinical Use of

Antithrombotic Therapy, Angiolillo et al, eds. Informa Press, London, 2008, pp. 189-

196.

70. Herrmann HC. Percutaneous Repair of Mitral Regurgitation with the MitraClip

System. Touch Briefings: US Cardiovascular Disease 2008, Imprenta Colour Ltd.,

2008; Issue 3, p. 39-40.


71. Herrmann HC. Guide Catheters and Hemodynamic Support Devices in CathSAP

version 3, Cardiac Catheterization and Interventional Cardiology Self-Assessment

Program, Moliterno D, editor-in-chief, ACC Foundation 2008, Chapter 41, pp. 474-

479.

72. Bannan A and Herrmann HC. “Transseptal Catheterization in the Adult,” in

Complications During Percutaneous Interventions for Structural and Valvular Heart

Disease, Hijazi Z, Feldman T, Cheatham JP, Sievert H, eds., Informa 2009, London,

pp. 304-310.

73. Moghbeli N and Herrmann HC. “Mitral Stenosis” in Valvular Heart Disease, Wang

and Bashore, eds., Human Press 2009; pp. 207-219.

74. Herrmann HC. Circulation: Cardiovascular Interventions. 2008;1:159-160 (Editorial).

75. Herrmann HC. Transcatheter Mitral Valve Implantation. Cardiac Interventions Today

2009;3:82-85.

76. St. John Sutton M, Herrmann HC, Donner RM. Cyanosis in Ebstein Anomaly and

Catheter Closure of Atrial Septal Defect, in Cases in Adult Congenital Heart Disease,

Gatzoulis, Webb, Broberg, Uemura, eds., Elsevier, Philadelphia, 2010, pp. 188-193.

77. Bannan A, Herrmann HC. “Interventions in Cardiogenic Shock” in Textbook of

Interventional Cardiology, 6th edition, Topol EJ and Teirstein PS, eds. Elsevier

Saunders, 2012, Philadelphia, pp. 263-269.

78. Naidu SS, Herrmann HC. “Support Devices for High-Risk Percutaneous Coronary

Interventions” in Textbook of Interventional Cardiology, 6th edition, Topol EJ and

Teirstein PS, eds. Elsevier Saunders, 2012, Philadelphia, pp. 455-466.

79. Bui QT and Herrmann HC, “Building a Structural Heart Disease Program,” in

Structural Heart Disease Interventions, Carroll JD and Webb JG, eds., Lippincott

Williams, and Wilkins, 2012, Philadelphia, pp. 3-9.

80. Anwaruddin, S and Herrmann HC. Old Dog, New Tricks: Redefining the Role for

Balloon Aortic Valvuloplasty in the Transcatheter Aortic Valve Replacement Era. J

Invasive Cardiology, invited commentary, Feb, 2012.

81. Herrmann HC. Patent Foramen Ovale and Atrial Septal Defect in Interventional

Cardiology 1001 Questions: An Interventional Cardiology Board Review, Mukherjee

D, Cho L, Moliterno DJ, eds, 2012, Wolters Kluwer / Lippincott Williams & Wilkins,

Philadelphia, pp 398-405.

82. Herrmann HC. An Interventionalist’s Approach to the Practical Use of TEE Guidance

in Atlas of Percutaneous Mitral Valve Edge-to-Edge Repair, Feldman T, Rogers J, Yeo

K, eds. Springer-Verlag, London, 2012 (in press).


83. Herrmann HC. Percutaneous Mitral Valve Repair and Replacement in Valvular Heart

Disease – A Companion to Braunwald’s Heart Disease, Bonow R and Otto C, eds., 4th

Edition, Saunders, Chapter 22; 2013:341-352.

84. Shreenivas S and Herrmann HC. Case of Large Left Atrium in Atlas of Percutaneous

Mitral Valve Edge-to-Edge Repair, Feldman T, Rogers J, Yeo K, eds. Springer-Verlag,

London, 2012 (in press).

85. Bortnick A, Silvestry F, and Herrmann HC. Intracardiac Echocardiography (Chapter

2.10) in Percutaneous Interventional Cardiovascular Medicine The PCR EAPCI

Textbook, Eeckhout E, Serruys P, Wijns W, Vahanian A, Van Sambeek M, DePalma

R, editors. PCR Publishing 2012; pp 555-574.

86. Giri J, Szeto WY, Bavaria J, Herrmann HC. Transcatheter Aortic Valve Replacement

With Coronary Artery Protection Performed in a Patient With an Anomalous Left

Main Coronary Artery. J Am Coll Cardiol 2012;60:e9.

87. Bortnick AE, Gordon E, Gutsche J, Anwaruddin S, Szeto WY, Desai N,

Vallabhajosyula P, Bavaria JE, Herrmann HC. Percutaneous Closure of a Left

Ventricular Psudoaneurysm After Sapien XT Transapical Tranascatheter Aortic Valve

Replacement. J Am Coll Cardiol Intv. 2012;5(12):e37-38

88. Shreenivas SS, Lilly S, Desai ND, Farooki A, Cheung AT, Acker MA, Herrmann HC,

Anwaruddin S. Percutaneous Closure of an Aortic Pseudoaneurysm Due to Saphenous

Vein Graft Dehiscence With an Amplatzer Vascular Plug. JACC: Cardiovasc Intv

2013;6:1103-4.

89. Lilly SM, Rome J, Anwaruddin S, Shreenivas S, Desai N, Silvestry FE, Herrmann HC,

Fassa A, Himbert D, Brochet E, Labbe JP, Depoix JP, Hvass U, Vahanian A,

Holoshitz N, Kenny D, Hijazi ZM. How Should I Treat Prosthetic Tricuspid Stenosis

in an Extreme Surgical Risk Patient? EuroIntervention 2013;9(3):407-9.

90. Kadakia MB, Ogbara J, Prasanna V, Herrmann HC, Silvestry FE. Echocardiography

in Percutaneous Interventions, Chapter 14. EchoSAP, ACC Foundation 2014 (in

press).

91. Kadakia MB, Silvestry FE, Herrmann HC. Intracardiac Echocardiography-Guided

Transcatheter Aortic Valve Replacement. Catheterization and Cardiovasc Interv

2015;85:497-501.

92. Mitul B. Kadakia, MD, Sourin Banerji, MD, Joyce Wald, DO, Dinesh Jagasia, MD,

Howard C. Herrmann, MD. Left Ventricular Pseudoaneurysm following Dor

Procedure: Successful Percutaneous Closure With an Amplatzer Duct Occluder II

Device. J Interventional Cardiology 2014 (submitted).

93. Anwaruddin S and Herrmann H. “Transcatheter Mitral Valve Intervention” in

Catheter Interventions – A Companion to Braunwald’s Heart Disease, Bhatt D, ed.,

Saunders, Chapter 30; 2014, pp. 482-497.


94. Herrmann HC and Maisano F. Transcatheter Therapy for Mitral Regurgitation

(Invited Review). Circulation 2014;130:1712-1722.

95. Herrmann HC and Han Y. Identifying patients who do not benefit from transcatheter

aortic valve replacement. Circulation: Cardiovascular Interventions 2014;7(2):136-8.

96. Naidu SS, Herrmann HC. “Support Devices for High-Risk Percutaneous Coronary

Interventions” in Textbook of Interventional Cardiology, 7th edition, Topol EJ and

Teirstein PS, eds. Elsevier Saunders, 2016, Philadelphia, pp. 576-589.

97. Shreenivas SS, Lilly SM, Herrmann HC. “Interventions in Cardiogenic Shock” in

Textbook of Interventional Cardiology, 7th edition, Topol EJ and Teirstein PS, eds.

Elsevier Saunders, 2014, Philadelphia, pp. 368-374.

98. Maisano F, Alfieri O, Banai S, et al. The future of transcatheter mitral valve

interventions: competitive or complementary role of repair vs. replacement? European

Heart J 2015;doi:1093/eurheartj/ehv123.

99. Kobayashi T, Giri J, Vallabhajosyula P, Herrmann HC, Jagasia D. Overestimation of

Paravalvular Leak with Edwards Sapien 3 Transcatheter Aortic Valve Replacement.

2015;5:e69-71.

100. Herrmann HC. New Transcatheter Aortic Valve Prosthesis Sets a New Standard. J

Am Coll Cardiol 2014;64(21):2244-2245.

101. Mark S, Prasanna V, Ferrari V, and Herrmann HC. Percutaneous VSD Closure After

Sapien 3 TAVR. 2014 (submitted).

102. Anjan VY, Herrmann HC. All Aortic Stenoses Are Not Created Equal. J Am Coll

Cardiol 2015;65:654-6.

103. Herrmann HC and Mack MA. “Transcatheter Therapies for Valvular Heart Disease,”

in Heart Disease, Braunwald E., editor. Elsevier Press. 2017 (in press).

104. Herrmann HC. Transcatheter Mitral Valve Repair and Replacement,” in Valvular

Heart Disease, Otto and Bonow, editors. Elsevier Press 2017 (in press).

105. Herrmann HC and Chitwood WR. Transcatheter mitral valve replacement clears the

first hurdle. J Am Coll Cardiol 2017;68:xxx-xxx.

106. Julien MB, Desai N, Brozena S, Herrmann HC. Transcatheter aortic valve

replacement for bicuspid aortic stenosis 13 years post heart transplant. Card Revasc

Med 2017 (submitted).


Contributions to peer-reviewed clinical research publications, participation cited but not by

authorship:

1. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary stent

placement and balloon angioplasty in the treatment of coronary artery disease. N Engl

J Med 1994;331:496-501.

2. The RESTORE Investigators, The effects of platelet glycoprotein IIb/IIIa blockade

with tirofiban on adverse cardiac events in patients with unstable angina or acute

myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-

1453.

3. The PRISM-PLUS Investigators, Inhibition of the Platelet Glycoprotein IIb/IIIa

Receptor with Tirofiban in Unstable Angina and Non-Q-Wave Myocardial Infarction.

N Engl J Med 1998;338:1488-97.

4. The PRISM Investigators, A Comparison of Aspirin Plus Tirofiban With Aspirin Plus

Heparin for Unstable Angina. N Engl J Med 1998;338:1498-505.

5. Pursuit Trial Investigators, Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide

in Patients with Acute Coronary Syndromes. N Engl J Med 1998;339:436-43.

6. Kereiakes DJ, MD; Kleiman NS, MD; Ferguson JJ, MD; Masud ARZ, MD; Broderick

TM, MD; Abbottsmith CW, MD; Runyon JP, MD; Anderson LC, RN, BSN; Anders

RJ, PharmD; Dreiling RJ, MD; Hantsbarger GL, MS; Bryzinski B, MD; Topol EJ,

MD; for the Oral Glycoprotein IIb/IIIa Receptor Blockade to Inhibit Thrombosis

(ORBIT) Trial Investigators. Circulation 1998;98;1268-1278.

7. Trial of Abciximab With and Without Low-Dose Reteplase for Acute Myocardial

Infarction. Circulation 2000; 101:2788-2794.

8. Moliterno DJ, Topol EJ, for the Target International Steering Committee. A direct

comparison of tirofiban and abciximab during percutaneous coronary revascularization

and stent placement: Rationale and design of the TARGET trial. Am Heart J

2000;140:722-6.

9. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and

conservative strategies in patients with unstable coronary syndromes treated with the

glycoprotein IIb/IIIa inhibitor tirofiban. New Engl J Med 2001;344:1879-87.

10. GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with

fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet

glycoprotein IIb/IIIa inhibition: the Gusto V randomized trial. Lancet 2001;357:1905-

14.


11. Nissen SE, Tuzcu EM, Libby P, et al. Effect of Antihypertensive Agents on

Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure:

The CAMELOT Study. JAMA 2004;292:2217-2226.


NEJM Journal Watch Cardiology (reviews):

Herrmann HC. Journal Watch for Cardiology, Mass. Medical Society, Waltham, MA:

1 Improving Internal Mammary Artery Bypass Graft Patency, 1995;1:1.

2 Should Mitral Regurgitation Be Corrected At Earlier Stages? 1995;1:8.

3 Directional Atherectomy of Protected Left Main Stenoses, 1995;2:11.

4 Age And Gender Differences In Coronary Calcium, 1995;1:13.

5 Stress Perfusion Imaging In Aortic Stenosis, 1995;1:13.

6 Transplant CAD Detected By Intervascular Ultrasound, 1995;1:14.

7 Benefits Of Front Loaded rt-PA In Acute MI (Timi 4 trial) 1995;1:16.

8 Echocardiographic Correlates of Aortic Stenosis Progression, 1995;1:21.

9 Outcomes Compared For Angioplasty vs. tPA for MI, 1995;1:22.

10 Umbrella ASD Closure and Predictors of Success by TEE, 1995;1:22.

11 Amlodipine, Atenolol Compared for Effects on Ischemia, 1995;1:26.

12 Women, Birth Weight And Cardiovascular Disease Risk, 1995;1:29.

13 Exercise Induced Mitral Regurgitation In Mitral Valve Prolapse, 1995;1:29

14 Angiography Vs. Intervascular Ultrasound Post PTCA, 1995;1:32.

15 TEC Atherectomy Not Better Than Balloon Procedure, 1995;1:36.

16 SPECT - Thallium Better Than ECG In Normals, Too, 1995;1:36.

17 Syndrome X Impairs Life-Styles But Not Long Term Survival, 1995;1:36.

18 Guidelines Developed For Signal Averaged ECG After MI, 1995;1:40.

19 DCA Not Better Than PTCA For Lesions In Vein Grafts, 1995;1:42.

20 Or Native Lesions, 1995;1:43.

21 Bioprosthetic Valves Confirmed to Need Anticoagulation, 1995;1:45.

22 DCA Not Superior For Ostial LAD Stenoses, 1995;1:51.

23 Natural History Of Unstable Angina, 1995;1:53.

24 Fish Flops Again, 1995;1:54.

25 Reducing Mitral Regurgitation in Inferior MI, 1995;1:60.

26 Better Thrombolysis With Reteplase, 1995;1:60.

27 ACE Gene May Predispose to Post MI Dilation, 1995;1:62.

28 Elevated Fibrinogen Predicts Restenosis, 1995;1:67.

29 Revascularization After Transplant, 1995;1:69.

30 A Closer Look Questions Whether CABG Volume Really Relates To

Outcome, 1995;1:75.

31 Repletion of L Carnitine After MI May Limit LV Remodeling; 1995;1:76.

32 VO2 Level Seems Bad Triage For Heart Transplant Candidates, 1995;1:77.

33 Pre-Infarction Angina Limits Infarct Size and Expansion, 1995;1:78.

34 Hirulog Plus Aspirin For Unstable Angina, 1995;1:83.

35 Opening Arteries, Even Late, Helps MI Patients, 1995;1:84.

36 Revascularization Beats Medical Therapy for Silent Ischemia, 1995;1:85.

37 MI, Reperfusion, and Cardiac Shock, 1995;1:85.

38 Young Adult As Relieved by Balloon Valvuloplasty, 1995;1:92.

39 PTCA Beats Medical Therapy in Indices of Life Quality, 1995;1:92

40 Quinidine vs. Sotalol for Atrial Fibrillation, 1995;1:92.


41 Radioactive Stents in Animal Models, 1995;1:93.

42 Coronary Disease, An Infectious Process, 1996;2:3.

43 Stents May Beat PTCA For Saphenous Vein Graft Stenoses, 1996;2:4.

44 Pravastatin Helps The Moderately Hypercholesterolemia, 1996;2:4.

45 L-Arginine Improves Cardiac Performance in CHF, 1996;2:4.

46 Medicine, PTCA Or CABG For Stenoses, 1996;2:13.

47 Timi-3B Follow-up Results At One Year, 1996;2:14.

48 Why Cardiologists?, 1996;2:18.

49 The Elderly And PTCA, 1996;2:20.

50 Amiodarone For V-Tach, 1996;2:23.

51 CABG Report Cards Shifting Sicker Patients Elsewhere, 1996;2:26.

52 Heparin Coated Stents Get Thumbs Up, 1996;2:27.

53 Ticlopidine, Aspirin And Stents, 1996;2:29.

54 Combination Or Monotherapy For Stable Angina, 1996;2:31.

55 Identifying Candidates For Early Discharge After MI, 1996;2:38.

56 Remodeling After MI: How Long To Treat?, 1996;2:39.

57 Predicting MR After Balloon Valvuloplasty, 1996;2:45.

58 Time Adjusted Thrombolysis Treatment, 1996;2:46.

59 Sequelae Of Great Arteries Transposition, 1996;2:47.

60 Benefit Of Late Thrombolysis In Non Q-Wave MI, 1996;2:54.

61 Opening Arteries After MI Improves Survival, 1996;2:54.

62 Antiplatelets Better Than Anticoagulants For Stent Occlusion, 1996;2:58.

63 Anticoagulation During Pregnancy, 1996;2:60.

64 Better Thrombolysis In Smokers, 1996;2:60.

65 Intervascular Ultrasound Predicts Restenosis, 1996;2:62.

66 Pacemaker Dysfunction Due To Mobile Telephones, 1996;2:63.

67 Calcium Channel Blockers Revisited, 1996;2:67.

68 Stress Echo Safe In Elderly Patients, 1996;2:68.

69 New Surgery For Cardiomyopathy, 1996;2:70.

70 More On Stenting Without Anticoagulation, 1996;2:71.

71 Assessing Myocardium, Thallium Or Sestamibi?, 1996;2:71.

72 Eligibility For Thrombolysis, 1996;2:77.

73 Sudden Death During Marathons, 1996;2:78.

74 Traponine T Predicts High Risk In Unstable, 1996;2:82.

75 Continuous Better Than Bolus Furosemide, 1996;2:85.

76 Platelet Activation After Stenting, 1996;2:87.

77 Platelet Antagonism In Unstable Angina, 1996;2:88.

78 Pharmacologic Stress Better In Left Bundle Branch Block, 1996;2:92.

79 Complex Stenoses More Likely To Progress, 1996;2:96.

80 Early Graft CAD Due To Virus?, 1996;2:97.

81 PTCA Prevents Ventricular Dilation, 1997;3:2.

82 Radial Artery Revascularization Improves Patency, 1997;3:7.

83 Platelet Inhibition Following Atherectomy, 1997;3:7.

84 Gender, Mortality and Thrombolysis, 1997;3:12.

85 Estrogens For Syndrome X, 1997;3:13.

86 Estrogens Improve Outcome After PTCA, 1997;3:13.

87 Antiplatelets Beat Anticoagulants After Stenting In Acute MI, 1997;3:14.


88 Stents Better Than PTCA Alone For Chronic Occlusions, 1997;3:15.

89 Monomorphic VT After MI Predicts Poor Outcome, 1997;3:15.

90 Outpatient Stenting, 1997;3:24.

91 Carotid Artery Stenting-An Alternative to Surgery, 1997;3:24.

92 Limited Benefits of Pacing for HOCM, 1997;3:26.

93 Cardiologists Do It Better!, 1997;3:28.

94 Beta-blockers Add Benefits After MI, 1997;3:30.

95 Vitamin C Deficiency promotes MI, 1997;3:35.

96 and Blood Donation Reduces Risk of MI, 1997;3:35.

97 Earthquakes and Cardiac Events, 1997;3:36.

98 PTCA beats Thrombolysis Even in Low-risk MI, 1997;3:37.

99 Left Ventricular Rupture Not Always Fatal, 1997;3:43.

100 Revascularization Best for Silent Ischemia, 1997;3:49.

101 Who Benefits From Amiodarone?, 1997;3:51.

102 Nonsurgical Treatment of HOCM, 1997;3:54.

103 Second-hand Smoke Increases CHD Risk, 1997;3:56.

104 No Benefit to High-Dose Digoxin, 1997;3:57.

105 In PTCA, Practice Makes Perfect, 1997;3:60.

106 Beta-blockers Reduce Odds of Death in CHF, 1997;3:67.

107 Thoracic Aortic Smoke - A New Sign, 1997;3:70.

108 PTCA is Effective for Stent Restenosis, 1997;3:71.

109 Nicotine Patch Safe in Stable CAD, 1997;3:75.

110 Is Myocardial Infarction an Infection, 1997;3:78.

111 Simvistatin and Impotence, 1997;3:81.

112 Heart Failure Program Reduces Admissions, 1997;3:82.

113 Functional Capacity Predicts Mortality, 1997;3:83.

114 Long-term Benefit with Abciximab, 1997;3:84.

115 Diabetics Also Benefit from Stents, 1997;3:84.

116 CABG with Internal Mammary Best for Diabetics, 1997;3:91.

117 Diabetic Retinopathy: A Marker for Ischemia, 1997;3:91.

118 Sestamibi Imaging in the Emergency Department, 1997;3:92.

119 Beer Binging Increases Fatal Mis, 1997;3:94.

120 Intracoronary Verapamil in Acute MI, 1997;3:98.

121 Troponins T and I Predict Outcome in Unstable Angina, 1997;3:99.

122 Long-term Outcome of the Ross Procedure, 1997;3:100.

123 New rt-PA Regimen Achieves Higher Patency, 1998;4:2.

124 Laser PTCA Adds No Benefit, 1998;4:3.

125 Which Risk Factors Affect CABG Outcome?, 1998:4:8.

126 Dobutamine vs. Treadmill Exercise Echo, 1998;4:8.

127 Primary Stenting for Acute MI, 1998;4:14.

128 Clinical Correlates of Postinfarction Ischemia, 1998;4:14

129 Early Cardiomyopathy in Asymptomatic Relatives?, 1998;4:20.

130 Aspirin Improves Survival in Heart Failure, 1998;4:25.

131 Stenting for Small Coronary Arteries, 1998; 4:26.

132 Percutaneous vs Surgical Commissurotomy, 1998; 4:26.

133 The BOAT Study: An Atherectomy Resurgence, 1998; 4:27.

134 Saruplase-A New Thrombolytic, 1998; 4:33.


135 How to Assess Stenosis Severity, 1998; 4:33.

136 Abciximab Improves Results in Unplanned Stenting, 1998; 4:35.

137 Triglyceride - A Forgotten Risk Factor, 1998; 4:39.

138 Warfarin Improves Survival in LV Dysfunction, 1998; 4:40.

139 Heparin and MI in the Elderly, 1998; 4:41.

140 Therapeutic Angiogenesis Has Arrived, 1998; 4:46.

141 Early Discharge After Primary Angioplasty, 1998;4:55.

142 MI’s More Frequent in Winter, 1998;4:58.

143 C-Reactive Protein Predicts Risk in Unstable Angina, 1998;4:59.

144 How Effective is Diet in Lowering Cholesterol?, 1998;4:62.

145 Payor Status Influences Use of Angiography, 1998;4:64.

146 Lamifiban and Heparin in Unstable Angina - PARAGON, 1998;4;69.

147 All Arterial Grafts Yield a Better Outcome, 1998;4:74.

148 Lowering Lipids Works in Women Too, 1998;4:75.

149 T-Wave Normalization Predicts Viability, 1998;4:77.

150 Thrombocytopenia, Abciximab, and PTCA, 1998;4:79.

151 Atrial Septostomy for Severe PPH, 1998;4:80.

153 IVUS-Guided Stenting Does Not Reduce Restenosis, 1998;4:86.

154 Abciximab Improves Primary Angioplasty Outcome, 1998; 4:85.

155 TEE Evaluation of Coronary Stenoses, 1998;4:80.

156 Oral IIb/IIIa Inhibitors Are Coming, 1998; 4:91.

157 Worse Stent Outcome in Insulin-Dependent Diabetics, 1998;4:94

158 Cardiologist-Treated Patients Have Lower Mortality, 1998;4:95.

159 Integrated Coronary Revascularization-A New Approach, 1998;4:96.

160 Serial Troponin Measurement Best for Risk Stratification, 1998;4:99.

161 Operator Experience Affects Stent Outcome, 1998;4:99.

162 The BARI Study: Gender and Revascularization, 1998;4:100.

163 Ethanol Septal Reduction for HOCM, 1998;4:103.

164 CT Separates Ischemic from Nonischemic Cardiomyopathy, 1999;5:3.

165 Lanoteplase Beats Alteplase in Acute MI, 1999;5:4.

166 Optimal PTCA is as Good as Stenting, 1999;5:9.

167 Late Primary Angioplastyt is Beneficial, 1999,5:14.

168 Abciximab Improves Coronary Flow After Stent Placement, 1999;5:15.

169 Enhanced Insulin Secretion Predicts Restenosis, 1999;5:16.

170 Glucose-Insulin-Potassium Infusion Improves MI Survival, 1999;5:17.

171 Benefits of Thrombolysis Persists at Ten Years, 1999;5:18.

172 Nuts Protect Women from Heart Disease, 1999;5:20.

173 Benefit of Pravastatin Reduced at Low LDL Levels, 1999;5:23.

174 Postprocedure CK Elevations Predict Risk, 1999;5:24.

175 CABG Versus PTCA in a Large Population, 1999;5:24.

176 Gene Transfer Induces Myocardial Angiogenesis, 1999;5:28.

177 Age-Independent Benefits of Primary Angioplasty, 1999;5:30.

178 CABG or PTCA in Diabetic Patients?, 1999;5:32.

179 Two-Year Follow-Up of Coronary Gamma Brachytherapy,1999;5:32.

180 Nonionic Contrast Media Not Thrombogenic, 1999;5:33.

181 Pravastatin Reduces Stroke, Too, 1999;5:33.

182 ACE Inhibitors Reduce Sudden Cardiac Death, 1999;5:38.


183 Periprocedural MI Reduces Clinical Restenosis, 1999;5:39.

184 Percutaneous Mitral Commissurotomy, 1999;5:39.

185 Coronary Pressure for Assessing Stent Deployment, 1999;5:40.

189 Stenting in Acute MI, 1999;5;45.

190 Sustained Benefit of Abciximab at One Year, 1999;5:55.

191 Beta-Blockers plus Ace Inhibitors for LV Dysfunction, 1999;5:56.

192 Persistent ST-segment Elevation Predicts Risk, 1999;5:57.

193 Abciximab Improves Early Infarct Artery Patency, 1999;5:62.

194 Oral Anticoagulation for Aortic Atheroma, 1999;5:63.

195 Is Clopidogrel as Good as Ticlopidine After Stenting? 1999;5:63.

196 Late Infarct Artery Reocclusion Predicts Mortality, 1999;5:64.

197 Primary Angioplasty at Community Hospitals, 1999;5:66.

198 Enhanced External Counterpulsation Reduces Angina, 1999;5:71.

199 Early Exercise Testing for Low Risk CAD Patients, 1999;5:73.

200 ACE Inhibitors Plus Aspirin Improve Survival Rates, 1999;5:76.

201 Delaying Vein Graft Disease in Women and Elderly, 1999;5:77.

202 Abciximab and Reduced-Dose Lytics Improve Patency, 1999;5:79.

203 Cilostazol Reduces Restenosis After PTCA, 1999;5:80.

204 Is Heparin Necessary After Angioplasty, 1999;5:80.

205 To Cath or Not to Cath After MI, 1999;5:81.

206 Preventing Embolization During Vein Graft Angioplasty, 1999;5:82.

207 Coronary Calcium Independently Predicts Extent of CAD, 1999;5:87.

208 Late Thrombosis After Intracoronary Brachytherapy, 1999;5:88.

209 Is Thrombolysis for Strokes Premature?, 1999;5:89.

210 “Bigger is Better” for Stents, Too, 1999;5:93.

211 Coronary Flow Reserve Recovers Earlier with Stenting, 1999;5:93.

212 LV Function Not Assoc with Post-CABG Survival, 1999:5:94.

213 Troponin T Status Predicts Cardiac Risk Better than Angio,1999;5:96.

214 Posterior Chest Leads Help Identify Acute MI, 1999;5:97.

215 Beta-Blockade Increases Survival in Diabetic MI Patients, 2000;6:1.

216 Early Dipyridamole Imaging Predicts Post MI Events, 2000;6:2.

217 Angiographic Patterns In-Stent Restenosis Predict Outcome,2000;6:3.

218 99% Early LIMA-LAD patency, 2000;6:15.

219 Do Diabetics Need Abciximab and Stents? 2000;6:16.

220 Enzyme Elevation, Vein Grafts, and Late Mortality 2000;6:16.

221 Beta-emitting Stents and Candy-Wrapper Restenosis 2000;6:22.

222 Abciximab Improves Myocardial Reperfusion 2000;6:25.

223 Adenosine is Cardioprotective 2000;6:25.

224 Percutaneous PFO Closure Promising 2000;6:38.

225 Nitroglycerin for Unstable Angina Due to Restenosis 2000;6:39.

226 Excess Coronary Deaths on Mondays 2000;6:40.

227 Outcomes in Acute MI Trials 2000;6:42.

228 Snoring and Heart Disease in Women 2000;6:42.

229 Abciximab Improves Survival in Diabetics… 2000;6:46.

230 But Fails to Reduce Restenosis After MI 2000;6:46.

231 In BARI, Better Survival for Diabetics at 7 Years With CABG 2000;6:54.

232 In EAST, Equal Survival at 8 Years with PTCA and CABG 2000;6:54.


233 Risks From Surgery Soon After Stenting 2000;6:55.

234 Unprotected LMCA Stenting 2000;6:63.

235 Beta Radiation for In-Stent Restenosis 2000;6:63.

236 Carotid Stenting for High-Risk Patients 2000;6:69.

237 Intracoronary Adenosine Improves Outcomes With Primary PTCA2000;6:70.

238 Thrombolysis Ineffective in the Elderly 2000;6:72.

239 Greater Benefit of Stents with Abciximab in Complex Lesions 2000;6:79.

240 Pseudothrombocytopenia with Abciximab Not Dangerous 2000;6:80.

241 IVUS Improves Stent Expansion 2000;6:85.

242 Early Results With Biodegradable Stents 2000;6:86.

243 Gene Defect Predicts Stent Complications 2000;6:86.

244 Coumarins Improve PTCA Outcome 2000;6:89.

245 Clopidogrel Safer Than Ticlopidine After Stenting 2000;6:93.

246 Provisional as Good as Sytematic Stenting 2000;6:94.

247 Long-term Aggressive LDL Lowering After CABG 2000;6:95.

248 Thrombolytics vs. Angioplasty in Elderly MI Pts 2000;6:96.

249 Therapeutic Angiogenesis with rFGF-2 2001;7:1.

250 One-year Follow-Up For Gusto-III 2001;7:2.

251 Covered Stents for Vein-Graft Lesions 2001;7:5.

252 Nonsurgical Septal Reduction for HOCM 2001;7:9.

253 Stents No Better Than PTCA in Small Vessels 2001;7:15

254 -Tn I Has Low Sensitivity for Cardiac Events in Unselected Patients 2001;7;17

255 Homocysteine Levels Predict Ischemic Injury in ACS Patients 2001;7:17

256 Low Support/Outward Expression Anger Promote Atherosclerosis 2001;7:18

257 Are Sirolimus-Coated Stents the Solution to Restenosis 2001;7:21.

258 Routine Stenting or Provisional, Doppler-Guided Stenting? 2001;7:21.

259 No Benefit of ACEI After Successful Thrombolysis 2001;7:24.

260 Thrombin Injection for Post-Cath Pseudoaneurysm 2001;7:25.

261 Radiation to Prevent Restenosis 2001;7:30.

262 Stents vs CABG for Multivessel Coronary Artery Disease 2001;7:31.

263 Conservative Management for Post-Lytic Non Q Wave MI 2001;7:32.

264 Clopidogrel Better than Aspirin After Bypass Surgery 2001;7:38

265 Complications of Femoral Artery Closure Devices 2001;7:39.

266 Septal Ablation for HOCM Reduces LV Hypertrophy 2001;7:46.

277 Ticlopidine Before Stenting Reduces Adverse Events 2001;7:47.

278 Results of Unprotected Left Main Coronary Stenting 2001;7:48.

279 Post PTCA Mortality in Diabetics and Restenosis 2001;7:48.

280 Guidelines for Percutaneous Coronary Intervention 2001;7:49.

281 Nicotine Patches Do Not Increase MI Risk 2001;7:52.

282 Plaque Temperature Predicts PCI Outcome 2001;7:56.

283 Catheter Based Myocardial Gene Transfer 2001;7:63.

284 Percutaneous In Situ Coronary Venous Arterialization 2001;7:63.

285 Warfarin for PTCA 2001;7:64.

286 Lower Risk and CRP Levels in Aspirin Takers With USA 2001;7:65.

287 Longer Antiplatelet Therapy Beneficial After Brachytherapy 2001;7:71.

288 Primary Angioplasty vs. Thrombolysis for Acute MI 2001;7:74.

289 Coronary Angiography for Low Risk Patients with Chest Pain 2001;7:78.


290 MRI Visualization of Microinfarction After PCI 2001;7:81.

291 Predicting Post-PCI In-Hospital Mortality 2001;7:81

292 Risk Stratification of Patients with Low Gradient Aortic Stenosis 2001;7:82

293 Women Benefit Less from Early Invasive Treatment of Unstable CAD 2001;7:82

294 Routine Exercise Testing Not Useful After Coronary Revasc 2001;7:82

295 Early Reperfusion Improves PTCA Outcomes for Acute MI Patients 2001;7:88

296 Pregnancy Risks for Women with Heart Disease 2001;7:88.

297 Readministration of Abciximab Causes More Thrombocytopenia 2001;7:92.

298 Elevated CRP Level Predicts PCI Risk 2001;7:93.

299 Stents Reduce Restenosis in Small Arteries 2002;8:2.

300 How Common Are Adverse Events After SVG Interventions 2002;8:3.

301 Rapid MI Exclusion with Point-of-Care Testing 2002;8:9.

302 Sirolimus-Eluting Stents to Prevent Restenosis? Part 2. 2002;8:13.

303 Folate Treatment Lowers Restenosis Rates After Angioplasty. 2002;8:14

304 Reducing Distal Embolization With Filter Protection. 2002;8:14.

305 Randomized Comparison of On-and Off-Pump CABG 2002;8:15.

306 CK-MB Release After CABG Predicts Adverse Events 2002;8:15.

307 Time to Treatment Affects ST-Segment Resolution in Acute MI 2002;8:17.

308 GP IIb/IIIa Inhibitors Improve Survival in Diabetic ACS Patients 2002;8:22.

309 WBC Count Predicts MI Mortality in the Elderly 2002;8:23.

310 Clopidogrel More Effective Than Ticlopidine After Stenting 2002;8:31.

311 Direct vs. Conventional Stenting for Acute MI 2002;8:31.

312 Brachytherapy Effective for Saphenous Vein Grafts 2002;8:34.

313 PCI vs CABG in High-Risk Patients 2002;8:39.

314 First Human Experience With Hyperoxemic Reperfusion 2002;8:39

315 Eptifibatide plus Low-Dose tPA for Acute MI 2002;8:39.

316 Obesity and PCI-A Paradox? 2002;8:47.

317 Completeness of Revascularization Affects Outcome in ARTS 2002;8:48.

318 Clinical Practice Guideline: Unstable Angina 2002;8:49.

319 Sauna Treatment for Heart Failure 2002;8:49.

320 Brachytherapy for SVG In-Stent Restenosis 2002;8:54.

321 Distal Protection in SVG Interventions 2002;8:54.

322 Percutaneous Left Atrial Appendage Occlusion 2002;8:55.

323 Transcatheter Atrial Septal Defect Closure 2002;8:55.

324 Sirolimus Eluting Stent Cures Restenosis 2002;8:61.

325 Delayed Restenosis After Use of a Paclitaxel-Eluting Stent 2002;8:61.

326 Transmyocardial Laser Revasc Fails to Improve Angina 2002;8:62.

327 Primary Angioplasty Beats Thrombolysis in Elderly MI Pts. 2002;8:72.

328 And in High Risk Acute MI Patients 2002;8:72

329 Percutaneous PFO Closure for Cerebral Ischemia 2002;8:72.

330 Post PCI Acute Renal Failure: Predictors and Outcomes 2002;8:73

331 Flu Shots After Angioplasty and After MI 2002;8:73.

332 Long-term Follow-up After Coronary Stenting 2002;8:80.

333 Feasibility of Prehospital Fibrinolysis 2002;8:81.

334 Minimally Invasive Surgery vs. Stenting of the LAD 2002;8:86.

335 Acetylcysteine Limited Benefit for Contrast-Related Nephrotoxicity 2002;8:87.

336 Clopidogrel Increases Postoperative Bleeding 2002;86:87.


337 Aspirin Plus Warfarin Beats Aspirin in Post-STEMI Reocclusion 2002;8:88.

338 Sildenafil Improves Exercise Capacity in CHF 2002;8:95.

339 Is Immediate Availability of Revascularization Linked with Outcome 2002;8:96

340 Troponin T Release After Elective PCI 2002;8:96.

341 Periprocedural CK-MB Elevation And Early Post-PCI Mortality 2002;8:97

342 Declining Need for Emergency CABG After PCI 2002;9:3

343 TnI Elevation After Vascular Surgery Predicts Mortality 2002;9:3

344 Clopidogrel Benefits a Range of ACS Risk Groups 2002;9:4

345 ASD Closure Improves Functional Capacity in Adults with Mild Symptoms

2002;9:18

346 Autologous Bone-Marrow Transplant for MI 2002;9:20

347 Percutaneous Aortic Valve Replacement for Calcific AS 2003;9:23.

348 Prednisone Reduces Restenosis in Patients with High CRP 2003;9:24.

349 Reducing Nephrotoxicity with Iso-Osmolar Contrast 2003;9:29.

350 Sirolimus-Eluting Stents for In-Stent Restenosis 2003;9:32.

351 GP IIb/IIIa Inhibition Not Helpful in SVG PCI 2003;9:32.

352 Is It Time to Replace Heparin Use During PCI? 2003;9:38.

353 Safe to Combine Enoxaparin with Eptifibatide During PCI 2003;9:39.

354 Adding Enoxaparin to Eptifibatide Improves ACS Outcomes 2003;9:39.

355 Atorvastatin-Clopidogrel Drug Interaction 2002;9:40.

356 CRP Has Prognostic Value in Women with the Metabolic Syndrome 2003;9:40.

357 The Athlete’s Heart: Echocardiographic Findings 2003;9:42.

358 Paclitaxel-Eluting Stent Prevents Restenosis 2003;9:45

359 More on Sirolimus-Eluting Stents for In-Stent Restenosis 2003;9:46

360 Aspirin Resistance Predicts Adverse Cardiovascular Events 2003;9:50.

361 Intracoronary Abciximab Limits MACE During Emergent PCI 2003;9:55-56.

362 Therapeutic Angiogenesis Remains Elusive 2003;9:56.

363 Might Ximelagartran Replace Warfarin for Nonvalvular Afib? 2003;9:64.

364 Fibrinolytic Therapy Benefits Patients 75 and Older. 2003;9:65.

365 Combination Reperfusion Therapy Revisited 2003;9:66.

366 Pre-PCI CRP Levels and Statin Use 2003;9:66.

367 Folic Acid Not Beneficial for Secondary Prevention 2003;9:70.

368 Primary Angioplasty Better During theDay 2003;9:71.

369 PCI for Chronic Total Occlusions Improves Clinical Outcome 2003;9:72.

370 Are the Benefits of Coronary Stenting Overstated? 2003;9:72.

371 Restenosis Patterns with Drug-Eluting Stents 2003;9:72.

372 Do Sirolimus-Eluting Stents Also Benefit ACS Patients? 2003;9:73.

373 Predicting Complete Heart Block After Alcohol Septal Ablation 2003;9:82.

374 Rapid Transfer for Primary Angioplasty Beats Fibrinolysis 2003;9:86.

375 Can Distal Protection Improve Primary Angioplasty Outcome 2003;9:87.

376 Mitral Regurgitation: To Repair or to Replace 2003;9:88.

377 Angioplasty vs. Medical Therapy: Long-Term Data 2003;9:94.

378 How Well Does TEE Predict Recurrent Stroke? 2003;9:95.

379 Clopidogrel-Atorvastatin Interaction Revisited 2003;9:97

380 High Volume Still Yields Better CABG Outcomes 2003;9:97.

381 Optimal Aspirin Dosage for ACS Patients 2004;10:1.

382 Hemofiltration to Prevent Contrast Nephropathy 2004;10:2.


383 Sirolimus-Eluting Stents After MI 2004;10:2.

384 Is Stress-Testing Safe Soon After Stenting? 2004;10:3.

385 On-Pump Beats Off-Pump CABG for Graft Patency 2004;10:21.

386 Stenting vs. Off-Pump CABG 2004;10:21.

387 Time to Treatment Affects the Relative Benefits of Reperfusion 2004;10:22.

388 Nitroglycerin and the New Drug for Erectile Dysfunction 2004;10:24.

389 Slow-Release, Paclitaxel-Eluting Stent Limits Restenosis 2004;10:29.

390 Abciximab Adds No Benefit to Clopidogrel in Low Risk PCI 2004;10:29.

391 Rebound Ischemic Events Soon After Heparin Discontinuation 2004;10:30

392 Erectile Dysfunction: Risk Factor for Cardiovascular Disease 2004;10:36.

393 Hyperglycemia Linked with TVR After PCI 2004;10:38-39.

394 Delays to CABG After Failed PCI: What Are the Risks 2004;10:39.

395 On-Pump vs. Off-Pump CABG: The Debate Continues 2004;10:39-40.

396 Real World Experience With Sirolimus-Eluting Stents 2004;10:40.

397 Case of Late Drug-Eluting Stent Hypersensitivity 2004;10:40.

398 Thrombus Formation on Interatrial Septal Closure Devices 2004;10:40-1.

399 Primary Angioplasty for STEMI: Delays Matter 2004;10:45.

400 A Stent or a Bicycle for Stable CAD? 2004;10:45.

401 Abciximab Alone vs Abciximab plus Reteplase Before Primary PCI 2004;10:46

402 Percutaneous Valve Replacement for Aortic Stenosis 2004;10:47.

403 Stenting vs CABG for Multivessel Disease: 3-yr Results 2004;10:55.

404 Abciximab Improves Survival After Primary PCI in High-Risk Patients

2004;10:63

405 Drug-eluting Stent With a Bioabsorbable Polymer 2004;10:63-64

406 Predictors of Stent Thrombosis with Sirolimus-Eluting Stents 2004;10:64

407 Sildenafil for Primary Pulmonary Hypertension? 2004;10:65

408 Folate Therapy Harmful After Stenting 2004;10:71.

409 Thrombocytopenia After GP IIb/IIIa Inhibition 2004;71:72.

410 Clinical Care Tools Can Improve AMI Care 2004;71:73.

411 Primary Angioplasty Without On-Site Surgery 2004;10:79.

412 Left-Main Stenting Ready for Prime Time? 2004;10:79.

413 How Early Should We Discharge STEMI Patients After PCI? 2004;10:81.

414 The Pathology of Q-Wave MI: An MRI Study 2004;10:87.

415 Coronary Artery Bypass Grafting Guidelines 2004;10:89.

416 Does Erectile Dysfunction Predict Silent Ischemia in Diabetics? 2004;10:90.

417 Devices for PFO Closure 2004;10:97-98.

418 Is Aspirin Sufficient After Biologic AVR? 2004;10:98.

419 Protected Carotid Stenting vs. Endarterectomy in High Risk Pts 2005;11:3.

420 Long-Term Mortality After Acute MI: US vs. Canada 2005;11:4.

421 Patency of Radial Artery vs Saphenous Vein Bypass Grafts 2005;11:13.

422 Neuropsychological Effects of Stenting vs. CABG 2005;11:13.

423 Stents for Rescue Angioplasty After MI 2005;11:14.

424 Outcomes with Combined Anticoagulant-Antiplatelet Therapy for Afib

2005;11:16.

425 Is Coronary Revascularization Beneficial Before Vascular Surgery? 2005;11:23

426 Predictors of Improved Quality of Life After PCI 2005;11:23.

427 Abciximab Adds No Benefit fo Clopidogrel in Diabetes with PCI 2005;11:23


428 Which Drug-Eluting Stent for In-Stent Restenosis? 2005;11:24.

429 Sirolimus-Eluting Stents for Small Vessels 2005;11:24.

430 Distal Protection Fails to Improve STEMI Outcome 2005;11:41.

431 Left-Main Stenting: The Final Frontier? 2005;11:41

432 Long Transfer Time for Primary PCI in the US 2005;11:41.

433 Interatrial Closure Procedures Might Resolve Migraines 2005;11:44.

434 Nesiritide and Risks for Renal Failure and Death 2005;11:48.

435 Timing of Surgery for Asymptomatic, Severe Aortic Regurg 2005;48:12.

436 CABG Better Than Stenting for Multivessel CAD? 2005;11:53.

437 A Low-Cost Strategy for Primary PCI 2005;11:54.

438 The Benefits of Abciximab in STEMI Patients 2005;11:54.

439 Drug-Eluting Stent Thrombosis in the Real World 2005;11:55.

440 Treatments for Hypoertrophic Obstructive Cardiomyopathy 2005;11:56.

441 BNP’s Prognostic Value in Mitral Regurgitation 2005;11:63.

442 Percutaneous Annuloplasty Reduces MR in Sheep 2005;11:63.

443 Does Late Reperfusion After STEMI Improve Outcomes? 2005;11:69.

444 Routine Invasive Therapy for UA/NSTEMI. 2005;11:70.

445 Is PCI Overused in Patients With Stable CAD? 2005;11:70.

446 Late Angiographic Stent Thrombosis. 2005;11:70-71.

447 Percutaneous Left Atrial Appendage Occlusion 2005;11:71.

448 Can Treatment Slow Progression of Coronary Calcification? 2005;11:75.

449 PCI Improves Outcome in AMI Patients with Cardiogenic Shock 2005;11:78

450 Is Surgery Best for HOCM? 205;11:80.

451 Invasive vs Conservative Management of NSTEACS 2005;11:85.

452 Fibrinolysis-Facilitated PCI for STEMI? 2005;11:86

453 Clopidogrel After Fibrinolysis, Before PCI. 2005;11:86.

454 Battle of the Drug-Eluting Stents 2005;11:87.

455 Raising the Bar for Paclitaxel-Eluting Stents 2005;11:88.

456 The Role of Aspirin in HF Patients with CAD 2005;11:95.

457 Renal Artery Stenting Improves Balloon Angioplasty Results 2005;11:97.

458 CABG vs PCI in Cardiogenic Shock 2005;11:97.

459 Clopidogrel: Optimal Loading Dose in Non- ACS Patients 2006;12:2.

460 Post-Stenting Antiplatelet Therapy: Further Insights 2006;12:3.

461 Postconditioning Improves Primary Angioplasty Results 2006;12:3.

462 Statins in ACS Patients: Intensity of Treatment, Timing of Benefit 2006;12:11.

463 After Failed Fibrinolysis, Rescue PCI is Best. 2006;12:13.

464 LMWH Promising After Post-STEMI Fibrinolysis 2006;12:14.

465 Allen’s Test Before Radial Artery Catheterization 2006;12:14-15.

466 An Attempt to Prevent Vein-Graft Failure After CABG 2006;12:15.

467 How Common is Excess Medication Dosing After NSTEACS 2006;12:24

468 Hypersensitivity Reactions Linked to Drug-Eluting Stents 2006;12:25.

469 Specialization in Primary PCI Yields Better Outcomes 2006;12:31.

470 Risk Scoring for In-Hospital Mortality After PCI and CABG 2006;12:31.

471 Enoxaparin vs UFH as Adjunct to Fibrinolysis in STEMI 2006;12:37.

472 Percutaneous Treatment of Vavlular Heart Disease 2006;12:38.

473 Sirolimus vs Paclitaxel Stents: Little Difference in REALITY 2006;12:39.

474 Pre-PCI Abciximab plus Clopidogrel in High-Risk NSTEACS 2006;12:46.


475 Drug-Eluting Stents vs. Brachytherapy for Bare Metal ISR 2006;12:46-7.

476 Percutaneous Aortic Valve Implantation: Mid-Term Follow-up 2006;12:47.

477 No Long-Term Benefit of Post-MI Bone Marrow Cell Transfer 2006;12:48.

478 Oral Rapamycin Tested for Restenosis Prevention 2006;12:55.

479 Clopidogrel Increases Bleeding in Off-Pump CABG 2006;12:56.

480 PCI Without On-Site Cardiac Surgery 2006;12:56.

481 Incomplete Revascularization Might Worsen Survival After PCI 2006;12:63

482 Predictors of Restenosis After Drug-Eluting Stent Use 2006;12:63

483 For Asymptomatic Severe MR, Watch and Wait? 2006;12:64

484 Is Exercise Testing Useful in Managing Asymptomatic MR? 2006;12:64

485 Guidelines for Valvular Heart Disease 2006;12:73

486 Drug-Eluting Stents vs CABG for Left-Main Disease 2006;12:75

487 Drug-Eluting Stents for Primary PCI in STEMI 2006;12:77

488 Profiling MI Patients with Drug-Eluting Stents Who Stop Thienopyridine

Therapy 2006;12:79

489 Which Type of Heparin for Elective PCI? 2006;12:79-80.

490 Thrombectomy: No Benefit in Primary PCI 2006;12:80.

491 Can CT Evaluate Left-Main Stent Patency? 2006;12:90

492 Percutaneous Mitral Annuloplasty for Functional MR 2006;12:91.

493 Major Bleeding After ACS Predicts Mortality 2006;12:91.

494 Another Front in the Drug-Eluting Stent Battle 2006;12:94.

495 New Meta-Analysis Confirms Benefit Invasive Therapy 2006;12:100.

496 The Value of Long-Term Clopidogrel After Stenting 2007;13:1.

497 Isolated cTnT Elevation After PCI 2007;13:3.

498 Paclitaxel-Coated Balloon Catheter for In-Stent Restenosis 2007;13:3.

499 Percutaneous Self-Expanding Aortic Valve Stent 2007;13:3-4.

500 Is Bivalirudin a Good Antithrombotic Choice in ACS Patients? 2007;13:4

501 Drug-Eluting Stent Thrombosis: Weighing the Evidence 2007;13:13-14.

502 No Benefit of Complement Inhibition in STEMI 2007;13:16-17

503 Sirolimus-Eluting Stents vs Bare-Metal Stents for SVG 2007;13:17.

504 The Stent Controversy Continues 2007;13:21-22

505 Another Concern About Drug-Eluting Stents? 2007;13:23.

506 Premature Discontinuation of Dual Antiplatelet Therpay After Stenting

Advisory 2007;13:23

507 Do Specialty Cardiac Hospitals Drive Regional Increases in Revascularization

Rates? 2007;13:35-6.

508 Does PCI Improve Survival and Prevent MI in Stable CAD? 2007;13:37.

509 Mortality Benefits of GPIIb/IIIa Inhibitors During Primary PCI. 2007;13:43-4.

510 Early Abciximab Improves Peri and Post Procedural Primary PCI 2007;13:50.

511 Atorvastatin Before PCI Benefits ACS Patients 2007;13:50.

512 Streptokinase Improves Microvascular Perfusion After PCI 2007;13:52.

513 Off-label Use of Drug-Eluting Stents 2007;13:57

514 Mechanisms of Late DES Thrombosis 2007;13:58.

515 PTCA Better Than Medical Therapy for Silent Ischemia 2007;13:59.

516 Prophylactic Revascularization Before Surgery is Unnecessary 2007;13:59.

517 Nonresponsiveness to Clopidogrel and Subsequent DES Thrombosis 2007;13:63

518 Is Enoxaparin Better than UFH for PCI After Fibrinolysis? 2007;13:63


519 Can Correcting MR Improve the Outcome of Surgical Revasc.? 2007;13:64

520 Same Day Discharge After PCI is Feasible 2007;13:64

521 Improving Door-to-Balloon Time for Patients with STEMI 2007;13:71.

522 Promising Initial Results with CoreValve Percutaneous AVR 2007;13:72.

523 Favorable Results with DES in Nonbifurcation Left Main PCI 2007;13:72.

524 Regionalizing Care for Acute MI Patients 2007;13:79.

525 On vs Off-Pump CABG: A Big Picture 2007;13:88

526 DES vs BMS: The Ontario Experience 2007;13:88.

527 Increased Mortality with SES in SVG 2007;13:89.

528 SES vs PES: A Meta-Analysis 2007;13:89.

529 Another Meta-Analysis of BMS vs DES 2007 ;13 :89.

530 BMS or DES for CAD 2007;13:90.

531 A Randomized Comparison of DES and BMS in LM lesions 2007;13:90.

532 Surgical Myomectomy After Alcohol Ablation for HOCM 2007;13:91.

533 Clopidogrel Nonresponse May Not Be a Class Effect 2007;13:96.

534 PFO is Associated with Cryptogenic Stroke, Even in Older Patients 2007;14:1

535 Persistent Troponin Elevation After ACS Predicts Mortality 2007:14:5.

536 Stent Thrombosis and Restenosis After Bare-Metal Stenting 2007;14:7.

537 Sirolimus-Eluting Stents Outperform Bare-Metal Stents in Diabetes 2007;14:7.

538 Proximal Protection for SVG PCI 2007;14:7

539 Focused Update: ACC/AHA PCI Guidelines 2008;14:11

540 Does Thrombus Aspiration Improve Outcomes of Primary PCI 2008;14:21.

541 Drug-Eluting Stents, Bare-Metal Stents, and Bypass Surgery 2008;14:21-22.

542 Are Sirolimus-Eluting and Paclitaxel-Eluting Stents Equivalent? 2008;14:22-23.

543 What is the Impact of Bleeding After Acute MI Treatment? 2008;14:24.

544 Abciximab vs Eptifibatide for Primary PCI 2008;14:32

545 Periprocedural Bleeding and PCI Outcomes 2008;14:32

546 Randomized Study of Left Main Stenting 2008;14:32-3.

547 Identification of an Omeprazole-Clopidogrel Interaction 2008;14:34.

548 Closure of PFO for Migraine Relief: A Study Headache 2008;14:42.

549 A New Drug-Eluting Stent on the Horizon. 2008;14:46-7.

550 Are High-Dose Tirofiban and DES Best for STEMI. 2008;14:47-8.

551 Stenting vs. Surgery for Left Main CAD 2008;14:48-9.

552 Erectile Dysfunction: A New Risk Factor for Heart Disease 2008;14:63.

553 In-Hospital Death After CABG: Preventable or Not 2008;14:64.

554 Bivalirudin Alone During Primary PCI 2008;14:67

555 Bare-Metal and Drug-Eluting Stnets: What’s the Bottom Line? 2008;14:67-8.

556 No Net Clinical Benefit for Bivalirudin During PCI 2008;14:70.

557 Intracoronary Versus Intravenous Abciximab Delivery 2008;14:70-71.

558 Can Adjustment of Clopidogrel Dosing Reduce Ischemic Events After Stenting

2008;14:71.

559 Results of Alcohol Septal Ablation for HOCM 2008;14:72

560 Functional Mitral Stenosis After Restrictive Annuloplasty 2008;14:72-73.

561 Aggressive Statin Treatment After Bypass Surgery 2008;14:73.

562 Somking Enhances Platelet Inhibition by Clopidogrel 2008;52:531.

563 Sirolimus vs Paclitaxel Eluting Stents in Diabetic Patients 2008;14:87.

564 Drug-Eluting Stents Beat Bare-Metal Stents in Acute MI Analysis 2008;14:88


565 Reperfusion for STEMI: Survival in the Real World 2008;14:88

566 Provisional Side-Brance Stenting at Bifurcations Safe and Effective 2008;14:89

567 Meta-Analysis of PCI in Stable Angina - Contrast with COURAGE 2008;14:89

568 Bicarbonate vs Saline for Preventing Contrast-Induced Nephropathy 2008;14:90

569 Migraine and PFO – A Population Based Study 2009;15:11-12.

570 Revasc of Unprotected LM Lesions in Octogenarians 2009;2:13-14.

571 DES vs CABG in Patients with Diabetes 2009;2:14

572 Which Stent Type is Best for Patients with Diabetes 2009;2:15.

573 Guidelines for Management Congenital Heart Disease in Adults 2009;2:17.

574 Long Term Follow Up after Alcohol Septal Ablation 2009;15 (3):23-24.

575 How Should Clopidogrel Nonresponders Be Treated? 2009;15 (3):24-5

576 Which Stenting Technique is Best for Bifurcation Lesions? 2009;15 (3):27.

577 Predictors of Early Stent Thrombosis 2009:15(4):34

578 Bifurcations: When 2 Stents are Needed, What is Best Technique? 2009;15:34

579 Hybrid Revascularization – Is This the Future? 2009;15(4):35.

580 Which Revascularization Strategy is Best for Severe CAD 2009;15(4):36.

581 Brief Eptifibatide Infusion Safe After Uncomplicated PCI 2009;15:41-2

582 DES and BMS in Medicare-Eligible Patients 2009;15:42

583 Early Surgery Beneficial for Asymptomatic Severe MR 2009;15:43

584 DES vs BMS for SVG Lesions 2009;15:47-8

585 DES in patients with acute MI: reassuring results 2009;15:46

586 GP IIb/IIIa Inhibition After Clopidogrel Loading for Primary PCI 2009;15:55.

587 Long term F/U After Sirolimus-Eluting Stent Implantation 2009;15:55-56.

588 Which DES is Best for Left Main Lesions? 2009;15:56

589 Coronary Aneurysm After DES Implantation 2009;15:61.

590 Should Carotid STenting Be Performed in Octogenarians? 2009;15:63.

591 Invasive Procedures in Patients Taking Oral Anticoagulants. 2009;15:64.

592 Drive by Closure of Patent Foramen Ovale 2009;15:71-2

593 Predicting Outcome in Patients with Asymptomatic AS 2009;15:73.

594 Percutaneous Mitral Annuloplasty with Carillon Device 2009;15:77-8.

595 Statin Reload Beneficial in PCI 2009;15:81.

596 Surgical Backup for PCI 2009;15:81.

597 Should Coronary Angiography be Routine Before Vascular Surgery 2009;15:88

598 CABG After PCI 2009;15:89

599 Ischemic MR: Is Repair Better Thank Replacement? 2009;15:94.

600 Accelerated vs. Standard STK Infusion for Prosthetic Valve Thrombosis

2009;15:95

601 Two Clopidogrel Loading Doses Compared in Patient with STEMI 2009;16:6-7

602 Cangrelor is Not the New Champion 2009;16:7-8.

603 High Platelet Reactivity Associated with Adverse Events After LM Stenting

2010;2:11

604 High Dose Statins Before PCI. 2010;2:11.

605 Stent Gaps Detected by CT Angiography 2010;2:16.

606 Focused Update: STEMI and PCI. 2010;2:17.

607 Transcatheter Pulmonary Valve Implantation 2010;2:18.

608 Failure of Vascular Closure Devices. 2010;2:18-19.

609 A Better Treatment for Dialysis-Graft Stenosis 2010;16:3:25


610 High Risk PCI Supported with the Impella 2.5 Device 2010;16:3:27

611 Adherence to Guidelines for Coronary Revascularization 2010;16:32-3

612 Dual Anti-Platelet Therapy After DES: When to Stop? 2010;16:34

613 Silent Cerebral Embolism After Transcatheter AVI 2010;16:34-5

614 Outcomes of Endovascular vs Surgical Repair of AAA 2010;16:37.

615 What About Endovascular Repair of AAA in Inoperable Pts? 2010;16:37

616 Transcatheter Aortic Valve Implantation: Canadian Experience 2010;16:38

617 Intracoronary vs Intravenous Eptifibatide for PCI 2010;16:40

618 Triple Antiplatelet Therapy After Acute MI 2010;16:41

619 Invasive Strategies in NonSTEMI ACS- How Early is Early Enough 2010;16:47

620 A Comparison of Two DES Yields a Clear Winner 2010;16:47-48

621 Long-Term Outcomes of Alcohol Septal Ablation for HOCM 2010;16:51.

622 PFO Closure for Migraine Relief: A Persistent Headache 2010;16:51

623 Stenting v Endarterectomy for Carotid Stenosis: Trade-Offs? 2010;16:53

624 Endovascular AAA Repair: How Durable is the Benefit: 2010;16:59.

625 Valve Surgery for Asymptomatic Patients with Very Severe AS 2010;16:59

626 Avoiding Bleeding During PCI 2010;16:60.

627 Transcatheter Valve-in-Valve Implantation –A New Option for Failed

Bioprostheses 2010;16:64.

628 Do Statins Slow Progression of Rheumatic Mitral Stenosis? 2010;16:65.

629 Is Exercise Testing Necessary to Assess Degenerative MR? 2010;16:75.

630 When is D2B Time Most Important? 2010;16:82.

631 More European Results on TAVI 2010;16:82

632 How do Rates of Cardiac Interventions Compare in NY and Ontario 2010;16:87

633 Cooling Cardiac Arrest Patients: The Sooner, the Better? 2010;16:90-91.

634 More Controversy Over Clopidogrel 2010;16:94

635 Ten Year Findings of a Randomized Comparison of CAD Therapies 2010;64:95

636 Randomized Comparison of DES and BMS in Large Vessels 2010;17:1-2

637 Does Every Bifurcation Lesion Need a Kiss? 2011;17:15

638 Untangling the Benefits of DES in STEMI Patients 2011;17:15-16

639 Can We Identify Unstable Coronary Plaques Before They Rupture 2011;17:16

640 The Economics of Fractional Flow Reserve Measurement 2011;17:19.

641 Left Main CAD: Not Just for Bypass Anymore? 2011;17:34-35

642 Compassionate Use Variables Improve Risk Prediction for PCI 2011;17:35

643 High Dose Clopidogrel Fails to Reduce Events After Stenting 2011;17:36-7

644 Low Gradient AS with Preserved LV Function – A New Disease 2011;17:37-8

645 Unstable Angina/NSTEMI Focused Update ACC/AHA Guidelines 2011;17:46

646 Myocardial Injury Associated with TAVI. 2011;17:55.

647 Alcohol Septal Ablation Safe and Effective for HOC 2011;17:62-3.

648 Okay to Switch from Heparin to Bivalirudin Before Primary PCI 2011;17:64.

649 Watch Out fo Midventricular Obstruction in HCM 2011;17:70

650 Stem Cell Infusion to Reverse LV Remodeling Encouraging 2011;17:70

651 Percutaneous Tricuspid Valve Replacement: Outlook Good 2011;17:70-71

652 Door-to-Balloon Times: The US Earns a Pat on the Back 2011;17:73.

653 IABC Before Primary PCI Does Not Reduce Infarct Size 2011;17:74-5.

654 Culprit Vessel-Only Intervention Better tha Multivessel PCI 2011;17:75.

655 Can Atrial Fibrillation Cause MR? 2011;17:81.


656 All Drug-Eluting Stents Are Not Created Equal 2011;17:86.

657 Bicuspid Aortic Valve Increases Risk for Aortic Dissection 2011;17:86-7.

658 Is Same Day Discharge Safe After PCI? 2011;17:92.

659 Combining FAME and SYNTAX in a Functional Score Improves Risk

Assessment 2011;17:94.

660 Bioresorbable Stent Ready for Randomized Evaluation 2011;17:94-5.

661 Once Again, Bival Alone Beats Heparin plus a GPI 2012;1:6

662 DIDO: New Frontier in Improving AMI Treatment 2012;2:9.

663 Genotype Testing for Clopidogrel Responsiveness May Not Predict Events

2012; 2:16

664 Role of Alcohol Septal Ablation in HOCM 2012;18:17

665 Updated Guidelines: CABG and PCI 2012;18:23

666 Left Main PCI: Mapping the Territory 2012;18:31.

667 Safety of PCI at Hospitals Without On-Site Cardiac Surgery 2012;18:35.

668 Intracoronary Abciximab or Aspiration During Primary PCI 2012;18:36

669 A Snapshot of Real-World TAVR Results 2012;18:44-45

670 Long-Term Safety of Biodegradable Coronary Stents 2012;18:46

671 Optimal Platelet Inhibition for Primary PCI 2012;18:47

672 Should MR be Repaired During CABG 2012;18:62

673 Safety (and Risks) of Coronary Reactivity Testing in Women 2012;18:68

674 Focused Update: Management of UA/NSTEMI 2012. 2012;18:69

675 Refining Patient Selection for CRT. 2012;18:71-2.

676 Fractional Flow Reserve Garners More FAME 2012;18:74

677 Bleeding Risks with Triple Antithrombotic Therapy Quantified 2012;18:81

678 Durable Effects of In-Hospital Interventions After Out-of-Hospital Cardiac

Arrest 2012;18:86.\

679 Platelet Function Testing No Benefit in Coronary Stenting 2012;18:96

680 Warfarin Beneficial up to 6 Months After Bioprosthetic AVR 2013;19:5

681 Can Atorvastatin Reduce Contrast-Induced Acute Kidney Injury? 2013;19:11

682 An Encouraging Trial of a Mesh-Covered Stent in Primary PCI 2013;19:12

683 Paradoxical Low Flow AS May be Worse Than it Seems 2013;19:14

684 If Possible, STEMI Patients Should Go Straight to a Cath Lab 2013;19:23

685 Can We Build a Better SYNTAX Score? 2013;19:27.

686 Five-Year Results of the SYNTAX Trial. 2013;19:27

687 Immediate Fibrinolysis Compared with Delayed Primary PCI 2013;19:28

688 Elective PCI Without On-Site Surgery Deemed Acceptable 2013;19:32

689 FFR vs IVUS to Guide Revascularization Decisions 2013;19:37-38.

690 What is the Optimal Approach for Distal LM Stenting? 2013;19:46-47.

691 Mitral Valve Surgery in the Elderly Less Risky Than Previously Reported

2013;19:47.

692 Association of Post-PCI Bleeding and Mortality 2013;19:53

693 Natural History of Combined Aortic Stenosis and Regugitation 2013;19:53

694 TAVR for Aortic Regurgitation: Proceed With Caution 2013;19:54

695 Ichemia Testing Before CABG: What’s the Value Added? 2013;19:61

696 Who Will Do Well on Warfarin? Does it Matter? 2013;19:62-3

697 Should We Set a Higher Bar for Coronary Angiography? 2013;19:68-9

698 Randomized Trial of a Biodegradable Polymer Stent 2013;19:69-70


699 Skip the Emergency Department to Save Time 2013;19:70

700 PCI in Non-Infarct Related Arteries Improves Outcomes 2013;19:73

701 Routine Thrombus Aspiration: Another Negative Trial 2013;19:73-4

702 Access and Anticoagulation Strategies to Reduce Bleeding 2013;19:75

703 D2B Time: One Victory in a War on Many Fronts 2013;19:82

704 Which Antithrombotic Strategy Best in AF Patients… 2013;19:83-4

705 Intravenous Metoprolol Before Primary PCI 2013;19:88.

706 Mixed Findings for Prehospital Bivalirudin in Primary PCI 2013;19:89

707 Severe Functional Ischemic MR: Repair or Replace the Valve 2014;20:4

708 Outcomes After TAVR: First Report from the National Registry 2014;20:13-14

709 Aortic Valve Replacement in Medicare Recipients, 1999-2011 2014;20:14

710 Aortic Valve Calcification Distinguishs Severity in Discordant AS 2014;20:24

711 Medical Treatment, PCI, or CABG for Stable CAD? 2014;20:25

712 What is the Best Approach to Carotid Revasc. with CABG 2014;20:26

713 No Increase in Adverse Outcomes with New PPM After TAVR 2014;20:38

714 Two Studies of Self-Expanding Bioprosthesis for Severe AS 2014;20:38-9

715 Balloon-Expandable vs Self-Expandable Valves: CHOICE 2014;20:39

716 Guidelines: Management of Valvular Heart Disease in Adults 2014;20:48

717 Better Long-Term Survival With On-Pump vs Off-Pump CABG 2014;20:54

718 More Evidence for Early Surgery for Asymp Primary MR 2014;20:62

719 What’s the Best Revasc Procedure for LM CAD? 2014;20:63-64.

720 Is the Allen Test Necessary Before Transradial Artery Cath? 2014;20:64

721 Left Atrial Appendage Occlusion Similar to Warfarin Anticoag 2014;20:71

722 Can PFO Closure Reduce Decompression Sickness Scuba Divers 2014;20:71

723 TAVI for Failed Surgical Bioprostheses 2014;20:76

724 FFR Guided PCI Beats OMT for Severe Stable CAD 2014;20:78

725 Outcomes Improving for Cardiovascular Disease 2014;20:80.

726 Addressing MR in High-Risk Patients: Comparison of Approaches 2014;20:86

727 Are Bioabsorbable Stents Ready for Primetime? 2014;20:88

728 Bioprosthetic vs. Mechanical AVR in Younger Patients 2014;20:89.

729 Prolonged DAPT After Stent Implantation: Risks and Benefits 2015;21:1

730 Additional Studies Show No Benefit of Prolonged DAPT 2015;21:2

731 Should Moderate MR be Repaired During CABG? 2015;21:2-3

732 Warning: Early Structural Deterioration of an Aortic Bioprosthesis 2015;21:3-4

733 More Data on Left Atrial Appendage Occlusion 2015;21:4

734 Prasugrel Before PCI in NSTEMI Patients Is Not Beneficial 2015;21:9

735 Pooled Analysis of Bivalirudin During PCI 2015;21:10

736 Low Flow, Low Gradient AS with Preserved EF: Controversial 2015;21:16

737 Device to Narrow Coronary Sinus Effective for Angina 2015;21:17

738 A Falling Trend in US Coronary Revasc Procedures 2015;21:26

739 Vorapaxar Has Greater Net Benefit in Diabetics 2015;21:28

740 Occupational Health Risks in the Interventional Lab 2015;21:31

741 Randomized Trial of Complete vs Culprit PCI in STEMI 2015;21:39

742 CABG vs PCI for Multivessel CAD 2015;21:40

743 Biologic and Mechanical Mitral Prostheses: Outcomes 2015;21:41

744 A Personalized Bleeding-Avoidance Strategy Can Reduce PCI Bleeding

2015;21:42


745 Yet Another Randomized Study of Bivalirudin in MI Pts 2015;21:42

746 Does Public Reporting of PCI Outcomes Increase AMI Mortality 2015;21:43

747 Transacatheter and Surgical AVR Compared in All-Comers Trial 2015;21:54

748 LAA Occlusion to Prevent Stroke: A Viable Alternative 2015;21:71

749 Comparing Revasc Strategies in CAD Pts with CKD 2015;21:82

750 A paclitaxel-Eluting Stent Inferior to EES in DM 2015;21:89

751 Polymer-free DES Beats BMS in Pts with High Bleeding Risk 2015;21:89

752 A Fully Bioresorbable Vascular Scaffold Not Quite Ready 2015;21:90

753 Marked Decline in Nonacute and Inappropriate PCI in US 2016;22:1

754 Focused Update on Primary PCI for STEMI 2016;22:3

755 Repair vs Replacement in IMR: Outcomes at 2 Years 2016;22:8

756 Predictors of Readmission After TAVR 2016; 22:10-11

757 Recurrent MR after Primary Repair Linked to Mortality 2016;22:27-8

758 Can We Predict In-Hospital Mortality After TAVR 2016;22:34-5

759 For Ischemic CM, Bypass Surgery May Be Better After All 2016;22:35

760 TAVR in Nonagenarians 2016;22:43

761 TAVR for Bicuspid Aortic Stenosis: Is This the NextFrontier 2016;22:49-50

762 Does PCI of Chronic Total Occlusion Improve Survival? 2016;22:50.

763 Transcatheter MVR ins MAC Isn’t Easy 2016;22:70

764 Is This the Beginning of the End for BMS 2016;22:73-74.

765 In Hospitalized Heart Failure Patients, Too Little CAD Testing 2016;22:75.

766 Predictors of Early Cerebrovascular Events After TAVR 2016;22:78.

767 Incidence, Implications of Valve/Leaflet Thrombosis After TAVR 2016;22:78.

768 Update on DAPT Guidelines 2016;22:81-82

769 Unintended Effects of Public Reporting of PCI Mortality 2016;22:87.

770 Stenting of the Left Main Artery Noninferior to Bypass Surgery 2016;22:89

771 Future of Bioresorbable Scaffolds is Now in Doubt 2017;23:2

772 Can Cognitive Function Improve After TAVR 2017;23:9

773 Expert Consensus Statement on TAVR 2017;23:20

774 Frequency and Predictors of Readmission After TAVR 2017;23:21

Alternative Media:

1. Herrmann, HC. Indications and Outcomes with Stenting: 1995, ACCEL extended

learning tapes, volume 27, number 4, April, 1995.

2. Herrmann, HC. Management of Acute Coronary Syndromes, ACCEL extended

learning tapes, volume 29, number 12, December, 1997.

3. Herrmann, HC. Update on Diagnosis and Treatment of Mitral Stenosis, ACCEL

extended learning tapes, September, 1998.

4. Herrmann, HC. Guest on “Heart of the Matter” call-in radio show, WCTC, New

Brunswick, NJ, 3/5/99


5. Herrmann, HC. Management of Acute Coronary Syndromes: 1999, April 6. Virtual

Curriculum 2000: University of Pennsylvania School of Medicine Resource on the

World-Wide-Web;

URL:http://www.cu2000.med.upenn.edu/lectures/grandrounds.asp?event_id=96

6. Herrmann, HC. Ask the Doctor, WPEN 950 radio call-in show, Philadelphia, PA

5/4/03

7. Herrmann HC. Drug-Eluting Stents: Is the Cost Justified? Comment. Audio Journal

of Cardiovascular Medicine 2003;9(2): Track 3.

8. Herrmann, HC. Percutaneous Valve Repair and Replacement, ACCEL extended

learning tapes, November, 2004

9. Herrmann, HC. Facilitated PCI for Acute MI, ACCEL extended learning tapes, Vol.

37; No. 9 (September, 2005).

10. Herrmann, HC. Defining the role of thrombolytics in the management of STEMI.

www.theheart.org [ Satellite programs (CME) > Spotlight ] ; Mar 21, 2006.

Accessed at http://www.theheart.org/viewArticle.do?primaryKey=661279 on Mar 28,

2006.

11. Herrmann, HC. Percutaneous Valve Therapies: Overview of Percutaneous Mitral

Valve Approaches for Annular and Leaflet Repair. ACCEL, Sept 2008:40:9

Books and Monographs:

1. Herrmann, HC and Hirshfeld JW, editors: Clinical use of the Palmaz-Schatz balloon-

expandable stent. Futura Publishing Co., Inc., Mount Kisco, New York, 1993.

2. Herrmann, HC and Feldman T, editors: Percutaneous Transvenous Mitral

Commissurotomy with the Inoue Balloon. Supplement to Catheterization and

Cardiovascular Diagnosis, Wiley-Liss Inc, New York, 1994, 87 pp.

3. Herrmann HC. Editor: New Approachs to Revascularization in Acute Myocardial

Infarction and Stroke. Am J Cardiol supplement 2000;85:1C-51C.

4. Herrmann HC, Editor, Interventional Cardiology: Percutaneous Non-Coronary

Intervention, Humana Press, Totowa, NJ, 2005, 433 pp.

5. Herrmann HC and Henry TD, eds., Optimizing Reperfusion Outcomes in STEMI. Am

Heart J 2006;151 (suppl 1):S1-S39.

http://www.cu2000.med.upenn.edu/lectures/grandrounds.asp?event_id=96

http://www.theheart.org/viewArticle.do?primaryKey=661279


PATENTS:

1. Methods of Inhibiting Restenosis

Issued 6/10/97

#5,637,575.

2. Compositions and Methods for Modulating Growth of a Tissue in a Mammal

Issued 2/23/99

#5,874,419.

3. Methods of modulating tissue growth and regeneration

Issued 5/11/99

#5,902,799

4. Percutaneous Heart Valve

Herrmann HC, Mankame N, Ananthasuresy S.

PCT filed 7/20/04 (provisional filing 7/21/03)

Pub. NO: US 2007/0016286 A1 (pub date 1/18/07)

Issued November 24, 2009

#7,621,948

5. Device for Facilitating Cardioplegia Delivery in Patients With Aortic Insufficiency

Herrmann HC and Woo YJ

Issued August 16, 2011

#7,998,129

6. Valve Prosthesis Systems and Methods

Lamphere, Nguyen, Herrmann

App 20080208332, 8/28/08

Issued 7/13/10

# 7,753,949

7. Mitral Valve System

Lamphere D, Nguyen T, Herrmann HC, Tomba T, Gorman R, Gorman J

App 20080221672, filed 9/11/08

Issued 12/6/11

# 8,070,802

8. Percutaneous Heart Valve System (Divisional Methods Claims)

Herrmann HC, et al.. App 20100042208, filed 2/18/10

Issued 9/21/11

# 8,118,866


PRINCIPAL INVESTIGATOR OF GRANTS (Current/ongoing):

1. PARTNER 3: A Prospective, Randomized, Controlled, Multi-Center Study to

Establish the Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in

Low Risk Patients Requiring Aortic Valve Replacement who have Severe, Calcific,

Symptomatic Aortic Stenosis

2. PORTICO: Valve for Aortic Stenosis (St. Jude Medical Inc.)

3. REPRISE 3: US pivotal trial of Lotus Sadra transcatheter aortic valve replacement

(Boston Scientific, Inc.).

4. TOPAS-TAVI: Transcatheter Aortic Valve Implantation in Patients with Low-

Flow, Low-Gradient Aortic Stenosis. (Universite Laval)

5. SENTINAL: Cerebral Protection System-The SENTINEL System with TAVR

6. GALILEO: Global multicenter, open-label, randomized, event-driven, active-

controlled study comparing a rivaroxaban-based antithrombotic strategy to an

antiplatelet-based strategy after transcatheter aortic valve replacement (TAVR) to

optimize clinical outcomes.

7. 3D CARDIAC MRI VS CTA FOR TAVR: Use of systolic phase non-contrast 3D

cardiac MRI in the valvular assessment of patients undergoing transcatheter aortic

valve replacement (Sponsored Research Agreement, Edwards Lifesciences, Inc.)

8. COAPT: Clinical Outcomes Assessment of the MitraClip Percutaneous Therapy for

Extremely High Surgical Risk Patients (Abbott Vascular, Inc).

9. EDWARDS/CARDIAQ: Early feasibility study of transcatheter mitral valve

replacement in high risk patients with severe mitral regurgitation (CardiAQ Inc.).

10. SPARE-MR: A Feasibility Study of the Safety and Efficacy of SPanning Sutures

for Anterior-Posterior Reduction to Eliminate Mitral Regurgitation in Patients with

Symptomatic Heart Failure

11. PARACHUTE IV: Percutaneous Ventricular Restoration in Chronic Heart Failure

due to Ischemic Heart Disease (Cardiokinetix, Inc.)

12. REDUCE LAP: A study to evaluate the Corvia Medical, Inc. IASD® System II to

REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure

13. SHIELD II: Percutaneous Left Ventricular Assist Device (Heart Mate PHP) used

for patients undergoing high risk PCI (randomized vs Impella 2.5).


14. Bioflow-V: Device study of a new drug eluting stent with a biodegradable polymer

(Orsiro Stent). Drug is Sirolimus. Stent has short term advantage of a drug eluting

stent and once polymer biodegrades (3 yrs later) becomes a bare metal stent so has

long term advantage of BMS.

15. JOMED: Emergent Use of the JOSTENT GraftMaster Coronary Stent Graft for

Treatment of Coronary Artery Free Perforations (Abbott Vascular, Inc.)

16. REDUCE Trial of Helex device for PFO Closure (Gore, Inc.)

Download - CURRICULUM VITAE HOWARD CRAIG HERRMANN, M.D. …CURRICULUM VITAE HOWARD CRAIG HERRMANN, M.D. HOME ADDRESS: 732 Great Springs Road Bryn Mawr, PA 19010 (610) 519-1353 OFFICE ADDRESS:

Top Related